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Lay abstract 
Nuclear envelope (NE) linked diseases that range from neuropathy to muscular 
dystrophies to fat and bone disorders are a conundrum because the mutated proteins are 
ubiquitously expressed yet pathology is focused in particular tissues. The recent 
discovery of many tissue-specific NE proteins has led to the hypothesis that the tissue-
specific pathologies in NE-linked diseases is due in part to tissue-specific NE proteins 
interacting aberrantly with the mutated widely expressed proteins to mediate disease 
pathologies. Furthermore, NE linked muscle disorders often affect different distinct 
muscle groups. How specific muscle groups are affected is still unknown. It is postulated 
that if a NE protein were to contribute to muscle disease pathology, it will be specific for 
the muscle set affected. Such tissue-specific NE proteins could also be candidates for 
additional alleles in unlinked patients with similar presentations and indeed our 
preliminary sequencing data on unlinked Emery-Dreifuss muscular dystrophy patients 
suggests this to be the case. This study generated antibodies to several muscle-specific 
NE proteins and propose to test these on both control and muscular dystrophy patient 
cells to determine if they are aberrantly distributed in patient cells. Previous studies on 
NE-linked muscular dystrophies have revealed that several NE proteins involved in NE-
cytoskeletal connections are aberrantly targeted in patient cells. If these tissue-specific 
NE proteins are similarly mislocalised, this could prove to be a valuable diagnostic tool 
for muscle diseases that often have overlapping presentations and could pave the way 
for further mechanistic studies that could result in therapeutic interventions. This study 
also looks at the interaction between NETs and lamin A using a binding assay.
Abstract 
Many tissue-restricted diseases are linked to mutations in lamins and nuclear envelope 
transmembrane proteins (NETs). How these mutations in ubiquitously expressed 
proteins cause such defined diseases is still unknown. It is hypothesized that tissue 
restricted NETs that are partners of the nuclear lamins/existing linked proteins mediate 
tissue-specific disease pathologies. Proteomic studies have identified many tissue 
restricted NETs with effects on the cytoskeleton, gene positioning and regulation. This 
study investigates potential roles of candidate NETs in mediating tissue restricted disease 
pathology and their interactions with known factors such as emerin and lamins, mutations 
in which have been linked to a variety of tissue-specific dystrophies. This study looks into 
candidate tissue-specific NETs distribution in human tissues and in vitro using a solid 
phase binding assay to study candidate NETs interactions. I confirmed the tissue-
specificity of the candidate NETs in human and mouse tissue sections but did not find 
clear reproducible distribution of these NETs in patient tissue biopsy. One postulate is 
that NETs bind WT lamin for localisation and/or function and disruption of this interaction 
leads to disease. Using a solid phase binding assay approach to study NETs/lamin 
interactions, we demonstrate that Tmem120a, an adipocyte-specific NET binds WT lamin 
but has a reduced Bmax when tested for binding against a lipodstrophy causing lamin 
mutant (R482Q and G465D). This is consistent with the hypothesis that tissue-specific 
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The nuclear envelope (NE) (Fig. 1) is a double layer membrane, which separates the 
nucleoplasmic and cytoplasmic contents. It consists of the inner and outer nuclear 
membranes (INM/ONM), each with their own unique set of proteins and studded with 
nuclear pore complexes (NPC) (Hetzer 2010). Functionally, the NE has been linked to 
DNA damage repair, cell cycle regulation, gene regulation, cytoskeleton connections and 
cellular stress responses (Bermejo, Kumar, and Foiani 2012, Malhas and Vaux 2011, 
Srsen, Korfali, and Schirmer 2011, Tapley and Starr 2013, Van de Vosse et al. 2011). 
The protein diversity at the NE has long been thought to be uniform and ubiquitous across 
all tissues; as such it has presented a dilemma for the study of tissue-specific or tissue-
restricted diseases commonly termed laminopathies or nuclear envelopathies such as 
muscular dystrophies, lipodystrophies and progeria. These diseases have been linked to 
certain Nuclear Envelope Transmembrane proteins (NETs), and the nuclear lamina, both 
of which are widely expressed in most tissues (Worman, Ostlund, and Wang 2010). 
Further compounding the issue, mutations in one protein can cause multiple disorders 
(Worman, Ostlund, and Wang 2010). Another caveat of laminopathies or nuclear 
envelopathies is that mutations in multiple interacting proteins can cause variations of the 
same disorders. An example of this is cardiomyopathy with conduction defects, which 
was first linked to mutations in lamin A/C, but is also linked to mutations in lamin 
associated polypeptide 2  α (LAP2-α) (Taylor et al. 2005), a known interacting partner of 
lamin A (Dechat et al. 2000). Another disorder with multiple variants is Emery-Dreifuss 
muscular dystrophy (EDMD), for which genetic variants have been linked to emerin, 
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lamins, four and half limb 1 (FHL1), LUMA and the LInker of the Nucleoskeleton and 
Cytoskeleton (LINC) complex members (Mejat and Misteli 2010, Meinke, Nguyen, and 
Wehnert 2011, Meinke et al. 2014).  How these mutated proteins cause such a wide 
range of tissue-restricted disorders is still largely unknown. Mechanisms that attempt to 
explain the specific nature conundrum include mechanical stress, gene regulation and 
failure of stem cell maintenance. Currently, no one mechanism can fully explain the 
different pathologies and the fact that many of these disorders are linked to protein 
complexes suggests the hypothesis that: 
Tissue-restricted partner proteins may mediate the tissue-restricted pathologies of 
nuclear envelopathies. 
In this chapter, I will describe what is known about existing NETs and their functions and 
the pathology of laminopathies or nuclear envelopathies. I will present the data currently 
available about novel, tissue restricted NETs and their potential to mediate tissue 
restricted disorders. Finally, I will discuss the intricacy of NET interactions with each other 





Figure 1.Schematic of the nuclear envelope. The nuclear envelope is studded with NETs which have specific localization at the inner 
or outer NE. Some NETs such as nesprins and SUNs form the LINC complex which link the nucleoskeleton to the cytoskeleton. 
Nesprin proteins in the outer nuclear membrane (ONM) connect directly or indirectly to a variety of cytoplasmic filament systems 
(from left to right) mainly, actin, tubulin, and intermediate filaments (IFs). They also connect to more specialized structures such as 
on the right side of the NPC, TAN lines, and other nuclear envelope transmembrane (NET) proteins also appear to have interactions 
with cytoskeletal filaments (furthest right depiction) (Peter Meinke 2015). 
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1.1. Diseases of the nuclear envelope 
The largest organelle in a cell is the nucleus. The nucleus contains the DNA content of a 
cell, separated from the surrounding cytoplasm by a double layer lipid membrane, the 
nuclear envelope (NE). This is supported by a meshwork of protein termed the nuclear 
lamina. This meshwork provides the structural support for the NE. Surrounding the NE is 
the cytoplasm containing cellular organelles, positioning of which is determined by the 
microtubule network. The microtubule network, along with the actin and intermediate 
filaments make up most what is called the cytoskeleton. This group of protein filaments 
are responsible for cellular integrity. The intermediate filaments provide the mechanical 
strength while the other two filament types provide the dynamic functions. The actin 
filaments work in conjunction with another protein fibre called myosin to facilitate cell 
contraction, which is important for functions such as cytokinesis and cell motility. The 
cytoskeleton also provides a mean to which the nucleus is connected to the plasma 
membrane and the extracellular matrix (Figure 2) (Crisp et al. 2006, Kaminski, 
Fedorchak, and Lammerding 2014). This study will focus on the nuclear envelope and its 
protein complements. 
The NE and associated proteins have been linked to many diseases (termed “nuclear 
envelopathies/laminopathies), with a wide range of tissue-specific phenotypes linked to 
ubiquitously expressed proteins. Many of the proteins thus far linked to NE diseases are 
ubiquitously expressed. It has been previously thought that mutations in one gene cause 
one disease. However, this is not true, and perhaps the best example of this is lamin A 
(LMNA). Also, known as type V intermediate filament proteins (Burke and Stewart 2013), 
nuclear lamins play an important role in maintaining NE stability. There are two types of 
lamins, type A and type B. The majority of A-type lamins consists of lamin A and lamin 
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C, both encoded by the LMNA gene. B-type lamins consist mainly of lamin B1 and B2, 
encoded by two separate genes LMNB1 and LMNB2. Lamin C2 and lamin B3 belong to 
A-type and B-type lamins respectively, but are testis specific and will not be discussed in 
this report. Lamins have been shown to interact with NE associated proteins (Wilson and 
Foisner 2010) with potential roles in NE assembly and disassembly (Goldman et al. 
2002). The first two reports of a human disease caused by LMNA mutations were an 
autosomal dominant and a recessively inherited form of Emery-Dreifuss muscular 
dystrophy (EDMD) (Bonne et al. 1999, Raffaele Di Barletta et al. 2000). EDMD 
pathologies include early contracture of the elbows, Achilles tendons, rigidity of the spine, 
progressive muscle degradation in the upper arms and lower legs, and dilated 
cardiomyopathy with conduction defects (Emery 2000). Soon after, LMNA mutations 
were identified as the cause of two other diseases, dilated cardiomyopathy 1A and limb-
girdle muscular dystrophy (LGMD) (Fatkin et al. 1999, Muchir et al. 2000). Unlike EDMD 
however, LGMD patients lack the early joint contractures that are characteristic of EDMD, 
and in dilated cardiomyopathy 1A patients, skeletal muscle is either minimally affected or 
unaffected. Subsequently, LMNA mutations have been linked to Dunnigan-type familial 
partial lipodystrophy affecting fatty tissues (Cao and Hegele 2000, Shackleton et al. 2000, 
Speckman et al. 2000). The picture was further complicated by the discovery of LMNA 
mutations in an autosomal recessive form of Charcot-Marie-Tooth disease type 2, a 
hereditary motor and sensory neuropathy (De Sandre-Giovannoli et al. 2002). Mutations 
in LMNA have also been identified in autosomal recessive mandibuloacral dysplasia 
(MAD), a developmental disease that affects specific bones, but also has aspects of 
dermopathy and lipodystrophy (Novelli et al. 2002). Eriksson et al. 2003 also identified 
11 mutations in LMNA that cause Hutchinson-Gilford progeria syndrome, a premature 
18 
 
aging disease. These represent some of the major diseases that are caused by mutations 
in LMNA nuclear envelopathies (Eriksson et al. 2003). 
Mutations in other genes encoding NE proteins have also been linked to nuclear 
envelopathies. One of the most well-known NE proteins linked to envelopathies is emerin, 
which was first reported in X-linked EDMD (Bione et al. 1994, Bione et al. 1995). Emerin 
principally localizes at the INM (Manilal et al. 1996, Nagano et al. 1996) and interacts with 
lamin A. This interaction was shown to be important for localization of emerin at the NE 
(Clements et al. 2000, Fairley, Kendrick-Jones, and Ellis 1999, Sullivan et al. 1999). The 
range of diseases caused by mutations in the gene encoding emerin (EMD) , has been 
reported to be much wider than the original reported classical EDMD phenotype, which 
includes variants of EDMD and LGMD, along with dilated cardiomyopathy (Astejada et 
al. 2007). Genetic variants of EDMD have been linked to emerin, lamins, FHL1, LUMA 
and the LINC complex members (Mejat and Misteli 2010, Meinke, Nguyen, and Wehnert 
2011, Meinke et al. 2014). The LINC complex acts as an important bridge between the 
cytoskeleton and nucleoskeleton. This connection is required for mechanosensing and 
signal transduction between the extracellular matrix and the nucleus.  Disorders linked to 
the NE are varied and further complicated by genetic variants caused by interacting 
proteins.  
1.2. Lamins and diseases 
Lamins are type V-intermediate filaments (Steinert and Roop 1988). In mammals, there 
are four major forms of lamins; lamin A, C, B1 and B2, encoded by the LMNA, LMNB1 
and LMNB2 genes with lamin C being a splice variant encoded by LMNA. Lamins are 
expressed in most mammalian cells in various combinations, however, lamin A is mainly 
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expressed in differentiated cells (Lehner et al. 1987, Rober, Weber, and Osborn 1989, 
Stewart and Burke 1987). Lamins have different properties during mitosis, the A-type 
lamins remain soluble, while the B-types remain associated with membranes (Gerace, 
Blum, and Blobel 1978, Moir et al. 2000). Lamin A and C have been shown in vitro to be 
able to form heterodimers, but have only been found as homodimers in vivo (Schirmer, 
Guan, and Gerace 2001, Kolb et al. 2011).  
Among nuclear envelopathies, LMNA is the gene mutated most frequently with hundreds 
of reported mutations (http://www.umd.be/LMNA). Mutations in LMNA have been linked 
to many diseases, including muscular dystrophies, lipodystrophies, neuropathies and one 
of the most notable disorders, Hutchinson Gilford Progeria (Worman and Bonne 2007). 
Mutations in LMNA have been shown to interfere with folding, stability and assembly of 
the protein (Bank et al. 2011, Bank et al. 2012, Wiesel et al. 2008, Ben-Harush et al. 
2009, Bollati et al. 2012). These disruptions may contribute to the pathological 
mechanism(s) from which tissue-specific diseases arise.  
Lamins have many roles. Firstly, they form the structural components of the 
nucleoskeleton. Loss of or mutation of lamins have been shown to cause nuclear 
deformation (Lammerding et al. 2005). Indeed, change in nuclear shape is one of the 
effects of lamin mutations that leads to disease (Davidson and Lammerding 2014). The 
ratio of lamins is important for cellular properties and functions. Lamin A overexpression 
has been shown to increase nuclear stiffness and impair migration (Rowat et al. 2013, 
Harada et al. 2014). Conversely, nuclear fragility increases when lamin A is lost or 
reduced leading to increase in an nuclear rupture (De Vos et al. 2011, Hatch et al. 2013, 
Vargas et al. 2012). 
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Lamins also play a crucial role in mechanosignal transduction between the extracellular 
matrix (ECM) and the nucleus, via the LINC complex (Lombardi et al. 2011). It has been 
shown that interactions between the ECM and the nucleus affect levels of lamins and the 
structural properties of the cell and nucleus. Lamin regulation is important as the levels 
of the different isoforms are linked to cell fate and differentiation (Swift et al. 2013). 
Lamins have been found to interact with IMN NETs such as emerin (Clements et al. 
2000). These interactions are important as mutations in lamin A, emerin, nesprins and 
SUN proteins have all been linked to EDMD. This suggests that NET interactions may 
mediate disease pathology. We propose the hypothesis that: 
Tissue-specific NETs also bind lamins and that disease mutants of lamins and/or NETs 




Figure 2. Networks within the cell. The nucleus is connected to the cytoskeleton via the 
LINC complex which intern connects to the plasma membrane and the extracellular matrix 
via focal adhesion points, dystroglycan complex and cadherin. (Figure taken from 
(Kaminski, Fedorchak, and Lammerding 2014)) 
22 
 
1.3. Protein diversity at the nuclear membrane 
NETs have been shown to be important in many processes, such as myogenesis (Brosig 
et al. 2010), nuclear migration (Folker et al. 2011, Razafsky et al. 2012) and cell cycle 
regulation (Korfali et al. 2011). The dilemma of how mutations in widely expressed 
proteins as well as how mutations in the same proteins selectively cause different 
restricted pathologies in laminopathies gave rise to the postulate that other, tissue-
specific factors (i.e. other NETs) must be involved.  
The number of known proteins 
at the NE has increased in the 
last few years, many of which 
have been found to be tissue-
restricted. Three studies by the 
Schirmer lab revealed that only 
a third of putative NETs are 
shared between muscle, blood 
and liver tissues (figure 3) 
(Korfali et al. 2010, Wilkie et al. 
2011, Korfali et al. 2012). One 
hypothesis for the variation in 
the NE proteome in different 
tissues is evolutionary complexity. It has been reported that highly conserved proteins 
such as lamin B receptor (LBR),  Lamin A and B have homologs in yeast (Georgatos, 
Maroulakou, and Blobel 1989). It has been hypothesized that evolutionarily conserved 
proteins are more likely to contribute to central functions, and so are expressed in all 
Figure 3. Distribution of NETs idetified in different 
tissues. Only a third is shared between muscle, liver and 




tissues, while more recently evolved proteins are more likely to have evolved to fill specific 
functions, driving divergence of different tissues in higher organisms and so could be 
tissue-specific (Worman and Schirmer 2015). Many NETs have specific localizations, 
such as the LEM-domain proteins that exclusively reside at the INM, while others such 
as the nesprin proteins resides at the ONM. Emerin has been reported to have non-NE 
localisation such as intercalated discs (Cartegni et al. 1997) potentially explaining heart 
involvement in EDMD. However, a later study was unable to reproduce this finding 
(Manilal et al. 1999).  The three proteomic studies mentioned earlier identified hundreds 
of NETs from blood leukocytes, muscle and liver nuclei. So far 93 have been 
experimentally confirmed to target to the NE, and that only approximately 15% were 
shared between the different tissues (reviewed in (Worman and Schirmer 2015)). Some 
NETs are present in different tissues, while others show very specific expression. The 
discovery of novel tissue-restricted NETs poses the question, could any of these mediate 
disorders with tissue-restricted defects? It is postulated that mutations in the known 
linked, ubiquitously expressed proteins, disrupt interactions with tissue-specific 
component(s) resulting in pathology. NET interactions in tissue-specific disorders have 
been characterized in cases such as EDMD, where several linked proteins are known to 
be binding partners. It has been shown that nesprin 1 and 2 associate with EDMD linked 
proteins lamin A and emerin (Mislow, Holaska, et al. 2002) (Zhang et al. 2005). Along 
with interacting with already linked proteins, mutations in the nesprin binding, LINC 
complex member, SUN proteins have been linked to EDMD (Zhang et al. 2007) (Meinke 
et al. 2014). A clear example of tissue-specific NET linked to pathology is nesprin4, which 
has limited expression including the cochlea. Mutations in the gene enoding nesprin4 
correlate to a high frequency of hearing loss (Roux et al. 2009, Horn et al. 2013). 
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However, the tissue-specific components of most nuclear envelopathies/laminpathies are 
still elusive.  
So far, several tissue-specific NETs identified have been linked to diseases such as 
neonatal encephalocardiomyopathy (Tmem70)(Cizkova et al. 2008), Wolfram syndrome 
(WFS1) (Strom et al. 1998, Domenech, Gomez-Zaera, and Nunes 2002, Bespalova et al. 
2001) and a variant of EDMD,  linked to the NET designated as LUMA, with more 
promising candidates as mediators of disease, which will be discussed in later chapters. 
The evidence suggests that as we understand more about tissue-specific NETs, more 
will be revealed about tissue-specific disorders. 
1.4. Mechanisms underlying pathology 
With disorders, such as EDMD which so far had eight linked NE proteins, it is widely 
accepted that the mechanism(s) underlying tissue-specific disorders lie with or have links 
to the NE. Linked proteins have been found to be ubiquitously expressed. It is still unclear 
how seemingly widely expressed proteins cause tissue-specific diseases such as EDMD. 
Current mechanisms proposed to try and explain the pathology of these diseases 
includes gene regulation, mechanical stress and failure of stem cell maintenance 
(Gruenbaum and Foisner 2015).  
The nuclear envelope and its associated proteins have been documented to interact with 
chromatin, transcriptional regulators and to regulate gene expression (Zuleger, Robson, 
and Schirmer 2011, Gruenbaum and Foisner 2015).  Lamin A has been shown to bind 
the retinoblastoma susceptibility gene product (pRb) (Ozaki et al. 1994) and the LEM-
domain family proteins, which includes emerin, binds chromatin via interaction with the 
Barrier to Autointergration Factor (BAF) (Brachner and Foisner 2011). Loss of 
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heterochromatin at the NE periphery has been reported in autosomal dominant EDMD 
patients (Sabatelli et al. 2001) as well as loss of emerin altering heterochromatin 
distribution (Maraldi et al. 2006). Extensive roles of NETs with genome organisation make 
it a reasonable assumption that disruption of any regulatory interactions may lead to 
impairment of differentiation pathways, leading to muscle loss after damage.  
Failure of stem cell maintenance and differentiation could also help explain muscle loss, 
as if the population of muscle satellite cells are depleted, then muscles would lose their 
ability to replace damaged fibers. Impaired differentiation of several cell types such as 
muscle satellite cells, adipocytes and osteoblasts have been linked to LMNA mutations 
or dysregulation of their expression levels (reviewed in (Gruenbaum and Foisner 2015)). 
Complete LMNA knockout results in severe postnatal myogenic and adipogenenic 
development defects (Kubben et al. 2011). 
Nuclear envelope stability is very important and NE deformation is often a hallmark of 
disease (Davidson and Lammerding 2014). Studies have found NE deformation 
associated with LMNA and EMD(emerin) mutations (Lammerding et al. 2004) 
(Lammerding and Lee 2005) (Lammerding et al. 2005). Cultured primary cells from LINC 
complex deficient patients often show defects in nuclear morphology and impaired 
association with binding partners. Mutations in nesprins have all been found in the 
domain that binds to lamin or emerin. Defects in how cells deal with mechanical stress 
could lead to inability of muscle to repair damage caused by use. I will discuss the 
mechanical stress hypothesis in greater detail in the next section. 
There is evidence supporting all the mechanisms mentioned above, with advocates for 
each. However, no single mechanism sufficiently explains how tissue-specific diseases 
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arise. Most likely, depending on the disease, a combination of mechanisms is responsible 
for tissue-specific pathology. Recent studies by the Schirmer lab identified several tissue 
restricted NETs with roles in chromatin organization (Zuleger et al. 2013, Korfali et al. 
2010, Malik et al. 2014, Robson et al. 2016), association with the cytoskeleton (Wilkie et 
al. 2011) and differentiation (Batrakou et al. 2015). These proteins were identified in the 
proteomic studies mentioned in section 1.3 and their identification suggests that tissue-
specific NETs may have roles related to the disease mechanisms above and could 
potentially be involved in mediating tissue-specific pathology. 
1.5. Mechanical stress and NETs 
One main focus in this thesis will be testing the possibility of tissue-specific NETs 
contributing to defects according to the mechanical stress hypothesis. Several NETs 
were already implicated in mechanical stress, particularly ones from the LINC complex 
and mutations in all of these cause EDMD. In the case of nuclear envelopathies 
connected to mutations lamins and emerin, there are links to both gene regulation and 
mechanical stress. The discovery of mutations in nesprins and SUN proteins 
strengthened the idea of mechanical stress as a mechanism. The LINC complex 
connects the nucleoskeleton with the cytoskeleton (Figure 1). The cytoskeleton consists 
of filamentous proteins divided in to three main groups; microtubules, actin filaments and 
intermediate filaments. The largest of the three are microtubules with a typical diameter 
of 25 nm and are made up of the protein subunit tubulin.  Microtubules radiates out from 
a microtubule organising centre (MTOC) with the main MTOC being the centrosome. The 
microtubule network provides a structure which organelles used to define their 
positioning. Actin filaments are the smallest out of the three groups. They are important 
in cytokinesis and cell movement as they work alongside other filaments such as myosin 
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to allow for cell contraction. Intermediate filaments are strong but less dynamic than 
microtubules and actin filaments. They work alongside the other types to provide the 
mechanical support in a cell (O'Connor 2010).The core components of the LINC complex 
consist of the SUN INM protein family and the nesprins ONM (principally) protein family 
(Crisp et al. 2006). In mammals, several proteins have been grouped into the SUN family, 
as they all share a highly-conserved SUN domain that binds lamins; these include SUN1, 
SUN2, SUN3, SPAG4 and SPAG4L. The main members of the nesprin family are nesprin 
1 and nesprin 2, each of which has a diverse range of splice variants and some are more 
tissue-specific (Rajgor et al. 2012). Nesprins bind directly to SUN domain proteins 
through their Klarsicht/ANC-1/Syne homologue (KASH) domain (Zhou et al. 2012). There 
has been many reported combinations of SUN-domain and KASH-domain proteins that 
make up the LINC complex, the most common comprised of SUN2 and nesprin 1 (Meinke 
and Schirmer 2015). The crystal structure of this SUN2/nesprin 1 complex revealed a 
trimer of SUN-domain proteins interacting with a corresponding trimer of KASH peptide 
via a covalent disulphide bond (Sosa et al. 2012). Nesprins also bind the actin 
cytoskeleton via their N-terminal actin-binding (calponin homology, CH) domain 
(Taranum et al. 2012). Furthermore, the SUN2/nesprin2G LINC complex is required for 
transmembrane actin-associated nuclear (TAN) lines formation and nuclear movement 
(Luxton et al. 2011, Luxton et al. 2010).  
The involvement of the LINC complex in disease has been shown in several studies. 
SUN2 has been shown to be mislocalized in mouse models with absence or mutant A-
type lamins (Mejat et al. 2009). Also in mice, disruption of the KASH domain of nesprin-
1 led to having a phenotype that resembles EDMD (Puckelwartz et al. 2009). In humans, 
mutations in nesprin-1 and nesprin-2 have been linked to the pathology of EDMD (Zhang 
28 
 
et al. 2007). The nesprin isoforms nesprin-1alpha and nesprin-2beta binds to emerin; in 
X-linked EDMD, this interaction is disrupted (Wheeler et al. 2007). This implies that 
mutations in interacting partners of the LINC complex such as emerin can lead to defects 
in the complex, and that this disruption can lead to disease manifestation. This further 
emphasizes the importance of protein complexes in disease pathology, with strong 
evidence of the involvement of the LINC complex and associated NETs in disease. 
Mutations in nesprin-1 have also been reported to cause non-muscle related disease 
such as autosomal recessive cerebella ataxia (Gros-Louis et al. 2007). 
The evidence outlined above indicates an important role of NETs in linking the 
nucleoskeleton and cytoskeleton; they also show that this link is very important as 
disruption leads to disease manifestation. After the identification of tissue-specific 
proteins in the muscle dataset from the proteomic study performed the Schirmer lab, 
screens were carried out on these NETs (Table 1), to see whether any have cytoskeleton 
effects, as muscle-specific NETs with cytoskeletal connections could potentially mediate 
or lead to disease when disrupted. Over 60 NETs were exogenously expressed in U2OS 
cells, followed by fixation and immunofluorescence staining for cytoskeletal components. 
Microscopy was then used to identify any abnormalities in cytoskeleton component levels 
or organisation. For some NETs, siRNA knockdowns were also carried out. The 
observations of this screen include NETs colocalizing with microtubules at the nuclear 
surface, microtubule accumulation at multiple foci proximal to the nucleus without a 
distinctive microtubule organizing center (MTOC), vimentin disorganization, reduced 
actin filaments and altered SUN2 levels (Table 1). Out of the positive hits, the most 
promising candidates with functions that may mediate muscular dystrophy pathology 
were NET5, Tmem70, Tmem214 and WFS1. Research is on-going with these NETs with 
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little known about them. Mutations in Tmem70 has been linked to neonatal 
encephalocardiomyopathy and mutations in WFS1 has been linked to Wolfram 
syndrome. 
NET5, WFS1 and Tmem214 showed accumulation at the spindle base during mitosis, 
and Tmem214 appears to associate with microtubules at the nuclear surface (Wilkie et 
al. 2011). More strikingly, WFS1 and Tmem70 showed reduced SUN2 levels in 
knockdown experiments (unpublished data).  
In addition to the results from the cytoskeleton screen, NET5, also known as SAMP1, has 
been shown to be a component of transmembrane actin-associated nuclear (TAN) lines 
(Borrego-Pinto et al. 2012) which are required for the movement of the nucleus. TAN 
lines are formed when the LINC complex components nesprin-2G and SUN2 interact with 
actin. The study above showed SAMP1 to be a component of TAN lines and that it 
interacts with SUN2 and lamin A/C. They also show that the NE localization of SAMP1 is 
dependent on lamin A/C. This study supports the idea that SAMP1 could be an interacting 
partner with the LINC complex, and also supports the possibility that other proteins can 
take part in the same or similar interactions.  
Based on the phenotypes observed in the cytoskeletal screen, I planned on testing these 
NETs for changes in patient’s muscle tissues. 
1.6. Summary 
This thesis sets out to investigate the hypothesis that novel tissue restricted NETs are 
involved in mediating pathology in laminopathies/nuclear envelopathies. In chapter 3, I 
investigated the expression and the distribution pattern of several muscle specific NETs 
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in different muscle groups, to identify potential differences as different muscular 
dystrophies can have distinct phenotypes. I postulate that tissue-specific NETs could 
yield differences between muscle groups which may contribute to disease pathology. 
Chapter 4 compares differences between patients and control muscle tissues. I tested 
NETs expression and distribution patterns as a form of diagnostic marker. In chapter 5, I 
test the hypothesis that NETs may mediate disease pathology through interactions 
between linked, ubiquitously expressed proteins such as lamin A, and that disease-
causing mutations abolish or reduce these interactions leading to disease pathology.
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Materials and Methods 
2.1. Materials 
2.1.1. Bacterial strains and genotypes 
Table 2. Bacterial strains and genotypes 
DH5- F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR 
nupG Φ80dlacZΔM15 Δ(lacZYA-argF)U169 
hsdR17(rK- mK+) λ– 
BL21 F– ompT gal [dcm] [lon] hsdSB (mb-; rb-) 
BL21(DE3)-pLysS F- ompT hsdSB (rB-mB-) gal dcm(DE3) pLysS 
(camR) 
BL21(DE3)-pLysE F- ompT hsdSB(rB-mB-) gal dcm (DE3) pLysE 
(camR) 
BL21-CodonPlus(DE3)-RIPL E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal ? 
(DE3) endA Hte [argU proL Camr] 
StrataClone Solopack F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR 
nupG Φ80dlacZΔM15 Δ(lacZYA-argF)U169 





Table 3. Vectors used in the study 
pSC-B-Amp/Kan Intermediate vector used for blunt end cloning. 
pET28b HIS-tag protein expression vector. 
pMAL-CRI MBP-tag protein expression vector 
pGEX-4T1 GST-tag protein purification vector 
2.1.3. Buffers and solutions 
Table 4. Buffer used and composition 
Buffer Composition 
LB  1% (w/v) tryptone  
0.5% (w/v) yeast extract  
10 mM NaCl  
pH 7.4 
PBS (pH 7.2) 55 mM Na2HPO4 
154 mM NaCl 
PBS (pH 7.3) 55 mM Na2HPO4 
154 mM NaCl 
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pH adjusted with NaOH 
PBS (pH 7.4)  65 mM Na2PO4  
8.8 mM KH2PO4  
137 mM NaCl  
2.7 mM KCl  
TBS (pH 7.4) 25 mM Tris-Base 
137 mM NaCl 
2.7 mM KCl 
TAE 40 mM Tris-acetate  
1 mM EDTA  
DMEM Dulbecco's Modified Eagle's Medium 
(Lonza, 12-604F)  
RPMI 1640 Roswell Park Memorial Institute medium 
1640 (Gibco, 11875-093) 
Opti-MEM Opti-MEM® I Reduced Serum Medium 
(Gibco, 31985062) 
SDS-PAGE buffer 25 mM Tris pH 8.3  
192 mM glycine  
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0.1% (w/v) SDS  
Immunofluorescence blocking buffer 
(in PBS pH 7.2) 
1% (v/v) Horse Serum 
1% (v/v) Foetal Calf Serum 
0.1% (w/v) Bovine Serum Albumin 
MBP lysis buffer (pH 7) 10 mM Phosphate (pH 7.2) 
30 mM NaCl 
0.25% (v/v) Tween-20  
10 mM EDTA (pH 8) 
10 mM EGTA (pH 7) 
MBP elution buffer (pH 7) 10 mM Phosphate (pH 7.2) 
0.5 M NaCl 
1 mM NaAz 
1 mM EGTA (pH 7) 
10 mM Maltose 
MBP column buffer 20 mM Tris-HCl 
200 mM NaCl 
1 mM EDTA 
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Lamin/GST lysis buffer 25 mM HEPES (pH 8) 
0.1 M MgCl2 
3 mM 2-Mercaptoethanol 
Lamin solubilisation buffer 20 mM HEPES (pH 8) 
8 M Urea 
3 mM 2-Mercaptoethanol 
Skeletal muscle cell growth medium Promocell skeletal muscle cell growth 
medium (C-23060) 
Skeletal muscle cell differentiation 
medium 
Promocell skeletal muscle cell 
differentiation medium (C-23061) 
Acidified Acetone/Methanol mix 50% acidified Acetone (1 mM HCL) + 50% 
Methanol 
GST elution buffer 50 mM Tris-HCl, 10 mM reduced 
glutathione, pH 8.0 
HIS-Select Equilibration/wash buffer 50 mM sodium phosphate, pH 8.0, 
 0.3 M sodium chloride  
10 mM imidazole.  
HIS-Select Elution buffer 50 mM sodium phosphate, pH 8.0, 
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 0.3 M sodium chloride 
 250 mM imidazole 
2.1.4. Primary antibodies 
Table 5. Primary antibodies used in this study (IF – Immunofluorescence, WB – 
Western Blot) 







Myh1 Mouse 1:50 N/A 200 kDa Sigma (M1570) clone 
My-32 
Lamin A/C Rabbit 1:50 1:1000 70 kDa (Schirmer et al, 2001) 
Tmem38A Rabbit 1:50 1:200 30 kDa Millipore (06-1005) 
WFS1 Rabbit 1:50 1:200 100 kDa Proteintech (11558-1-
AP) 
Tmem214 Rabbit 1:50 1:200 70 kDa Proteintech (20125-1-
AP) 
NET5 Rabbit 1:20 1:100 70 kDa  




Emerin Mouse 1:50 N/A 29 kDa Glenn Morris (MANEM1 
(5D10)) 
Nesprin1 Mouse 1:50 N/A N/A Glenn Morris 
(MANNES1E (8C3)) 
Nesprin2 Mouse 1:50 N/A N/A Glenn Morris 
(MANNES1A (7A12)) 
Lamin A/C Mouse 1:50 N/A 70 kDa Glenn Morris 
(MANLAC1 (4A7)) 
SUN1 Rabbit 1:50 N/A N/A Atlas antibodies 
(HPA008346) 
SUN2 Rabbit 1:50 N/A N/A  
FHL1 Rabbit 1:50 N/A 32 kDa Aviva Systems Biology 
(ARP34378_T100) 
GFP Rabbit N/A 1:200 25 kDa Generated by Dzmitry 
Batrakou 
GFP Mouse N/A 1:1000 25 kDa Clontech (632381) 
H3 Mouse N/A 1:200 17 kDa Abcam (10799) 
MBP Mouse N/A 1:1000 42 kDa NEB (E8032L) 
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2.1.5. Secondary antibodies 
The table below lists all the secondary antibodies used in the study. The Licor IRDyes® 
listed were used for fluorescence based Licor Western blotting. The Alexa antibodies 
were used for immunofluorescence (IF). Anti-mouse Alexa 488 was also used to detect 
binding in the solid phase binding assay presented later in this thesis. 
Table 6. Secondary antibodies used in this study 
Antibody Host Dye Dilution Source 
Anti-
mouse 
Donkey Alexa 488 1:500 Invitrogen (A21202) 
Anti-
rabbit 
Donkey Alexa 488 1:500 Invitrogen (A21206) 
Anti-
mouse 
Donkey Alexa 568 1:500 Invitrogen (A10037) 
Anti-
rabbit 
Donkey Alexa 568 1:500 Invitrogen (A10042) 
Anti-
mouse 
Donkey IRDye® 800CW 1:1000 Licor (926-32212) 
Anti-
rabbit 





Donkey IRDye® 680CW 1:1000 Licor (926-68073) 
Anti-
rabbit 
Donkey IRDye® 680CW 1:1000 Licor (926-68073) 
2.1.6. Affinity matrixes 
Table 7. Affinity matrixes used in this study 
Matrix Source 
Amylose resin NEB (E8021L) 
Glutathione Sepharose 4B GE Healthcare (17-0756-01) 
HIS-Select® Nickle Affinity 
Gel 
Sigma-Aldrich (P6611) 
Affi-Gel® 10 Biorad (1536099) 
Pierce™ Nickel Coated 
Plates, Black, 96-Well 
ThermoFisher Scientific (15342 
2.1.7. Mammalian cells 
All primary human cells were acquired in compliance with ethical approval procedures 
and patient consent. 
Table 8. Cell lines used in this study 
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Cell line Type Source 
P2F1-g Hybridoma Developmental Studies Hybridoma Bank 
155/09 Primary human 
myoblast 
Muscle Tissue Culture Collection at the Friedrich-
Baur-Institut (Department of Neurology, Ludwig-
Maximilians-University, Munich, Germany) 
464/04 Primary human 
myoblast 
Muscle Tissue Culture Collection at the Friedrich-
Baur-Institut (Department of Neurology, Ludwig-
Maximilians-University, Munich, Germany) 
103/05 Primary human 
myoblast 
Muscle Tissue Culture Collection at the Friedrich-
Baur-Institut (Department of Neurology, Ludwig-
Maximilians-University, Munich, Germany) 
175/04 Primary human 
myoblast 
Muscle Tissue Culture Collection at the Friedrich-
Baur-Institut (Department of Neurology, Ludwig-
Maximilians-University, Munich, Germany) 
226/05 Primary human 
myoblast 
Muscle Tissue Culture Collection at the Friedrich-
Baur-Institut (Department of Neurology, Ludwig-
Maximilians-University, Munich, Germany) 
245/01 Primary human 
myoblast 
Muscle Tissue Culture Collection at the Friedrich-
Baur-Institut (Department of Neurology, Ludwig-
Maximilians-University, Munich, Germany) 
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402/03 Primary human 
myoblast 
Muscle Tissue Culture Collection at the Friedrich-
Baur-Institut (Department of Neurology, Ludwig-
Maximilians-University, Munich, Germany) 
GB2912 Primary human 
myoblast 
Muscle Tissue Culture Collection at the Friedrich-
Baur-Institut (Department of Neurology, Ludwig-
Maximilians-University, Munich, Germany) 
NH11-567A Primary human 
myoblast 
MRC Centre for Neuromuscular Disorders Biobank 
London 
NH13-1586A Primary human 
myoblast 
MRC Centre for Neuromuscular Disorders Biobank 
London 
6467 Primary human 
myoblast 
MRC Centre for Neuromuscular Disorders Biobank 
London 
NH11-567B Primary human 
fibroblast 
MRC Centre for Neuromuscular Disorders Biobank 
London 
NH13-1586B Primary human 
fibroblast 
MRC Centre for Neuromuscular Disorders Biobank 
London 
NH11-069B Primary human 
fibroblast 
MRC Centre for Neuromuscular Disorders Biobank 
London 
6468 Primary human 
fibroblast 




6217 Primary human 
fibroblast 
MRC Centre for Neuromuscular Disorders Biobank 
London 
2.1.8. Tissue sections 
Listed below are all the tissue sections used in this study. All human patient sections 
were acquired in compliance with ethical approval procedures and patient consent. 
Table 9. Tissue sections used in this study 
Section ID Type Source 
780 Human patient muscle 
sections 
Caroline Sewry, CIND, Oswestry 
NH10-648 Human patient muscle 
sections 
MRC Centre for Neuromuscular 
Disorders Biobank London 
NH11-069 Human patient muscle 
sections 
MRC Centre for Neuromuscular 
Disorders Biobank London 
NH13-1586 Human patient muscle 
sections 
MRC Centre for Neuromuscular 
Disorders Biobank London 
6680 Human patient muscle 
sections 
MRC Centre for Neuromuscular 
Disorders Biobank London 
6262 Human patient muscle 
sections 
MRC Centre for Neuromuscular 
Disorders Biobank London 
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5808 Human patient muscle 
sections 
MRC Centre for Neuromuscular 
Disorders Biobank London 
6424 Human patient muscle 
sections 
MRC Centre for Neuromuscular 
Disorders Biobank London 
227/02 Human patient muscle 
sections 
Benedikt Schoser, Friedrich-Baur 
Institute, Department of Neurology 
228/02 Human patient muscle 
sections 
Benedikt Schoser, Friedrich-Baur 
Institute, Department of Neurology 
233/02 Human patient muscle 
sections 
Benedikt Schoser, Friedrich-Baur 
Institute, Department of Neurology 
234/02 Human patient muscle 
sections 
Benedikt Schoser, Friedrich-Baur 
Institute, Department of Neurology 
271/02 Human patient muscle 
sections 
Benedikt Schoser, Friedrich-Baur 
Institute, Department of Neurology 
320/02 Human patient muscle 
sections 
Benedikt Schoser, Friedrich-Baur 
Institute, Department of Neurology 
2.1.9. Kits 




QuikChange II XL Site-
Directed Mutagenesis Kit 
Agilent Technologies (200521) 
2.2. Mammalian cell culture 
2.2.1. Cell maintenance 
Hybridoma cell lines were maintained in RPMI 1640 medium supplemented with L-
Glutamine and sodium pyruvate with 10% (v/v) FBS.  
Primary human myoblasts were maintained in skeletal muscle cell growth medium 
(PromoCell). Cells were kept from reaching confluency to avoid differentiation. 
Primary human fibroblasts were maintained in DMEM medium supplemented with 10% 
FBS (v/v). 
All cells were grown at 37oC in a 5% CO2 incubator. 
2.2.2. Primary human myoblast differentiation 
Primary human myoblasts were grown to confluency and changed into low serum 
differentiation medium (Skeletal muscle cell differentiation medium, Promocell). 
2.2.3. Production of monoclonal antibody from hybridoma cells 
Hybridoma cells were grown in suspension and withdrawn into serum free medium by 
50% every 2 days in 4 steps. The cultures were left to grow for up to a week to allow the 
production and secretion of the antibodies. Samples of medium supernatant were taken 
at regular intervals to test the level of antibody production and activity by Western blot. 
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The supernatant containing antibodies was cleared of debris by centrifugation at 1000 
RPM for 10 min and kept.  
2.3. Nucleic acid methods 
2.3.1. Sequencing of plasmid DNA 
The entire sequence of the cDNAs cloned into expression vectors was verified by 
sequencing. Sequencing was performed by the GenePool sequencing facility (University 
of Edinburgh). Provided chromatograms were analysed using the freeware program 
GENtle. 
2.3.2. Site-directed mutagenesis 
Lamin mutants were generated by mutating the cDNA sequence situated in the 
expression vectors. Mutagenesis was carried out using primers designed to be 
compatible with the protocol described in the QuikChange II XL Site-Directed 
Mutagenesis Kit. The mutagenesis procedure was carried out according to the kit’s 
protocol. 
Table 11. List of mutagenesis primers used in this study 
Lamin mutation Primers used 
E203K Forward: AACTGGACTTCCAGAAGAACA 
Reverse: TCTCCTTCATGGTCTGCAGC 




R377H Forward: AACTGGACTTCCAGAAGAACA 
Reverse: TCTCCTTCATGGTCTGCAGC 
R435C Forward: AACTGGACTTCCAGAAGAACA 
Reverse: TCTCCTTCATGGTCTGCAGC 
R453W Forward: AACTGGACTTCCAGAAGAACA 
Reverse: TCTCCTTCATGGTCTGCAGC 
G465D Forward: AACTGGACTTCCAGAAGAACA 
Reverse: TCTCCTTCATGGTCTGCAGC 
R482Q Forward: AACTGGACTTCCAGAAGAACA 
Reverse: TCTCCTTCATGGTCTGCAGC 
R527H Forward: AACTGGACTTCCAGAAGAACA 
Reverse: TCTCCTTCATGGTCTGCAGC 
2.4. Microscopy methods 
2.4.1. Immunofluorescence on cultured cells 
Adherent cells were grown on coverslips and washed in PBS to remove cellular debris 
and remaining serum prior to fixation with ice cold (-20oC) 100% methanol and 
immediately placed on dry ice or stored at -20oC. Following, the cells were washed for 10 
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min in PBS or TBS-0.1% Tween-20. Coverslips were blocked in 1X immunofluorescence 
blocking buffer (Table 1) for 20 min at room temperature (RT) and subsequently 
incubated with the appropriate primary antibody (dilutions listed in Table 2). Following 3 
washes in PBS or TBS-0.1% Tween-20, coverslips were incubated with goat secondary 
antibodies conjugated with Alexa Fluor® dyes (summarised in Table 3) and 4,6-
diamidino-2 phenylindole, dihydrochloride (DAPI) at a final concentration of 4 μg/ml 
(1:1000). All antibodies and dyes were prepared in blocking solution. Coverslips were 
then extensively washed in PBS or TBS-0.1% Tween-20 multiple times over the course 
of 30 minutes and then mounted on cover slips with VectaShield (Vector Labs). The 
coverslips were sealed in place using nail varnish.  
2.4.2. Human tissue section immunohistochemistry 
Tissue blocks were snap frozen using liquid nitrogen in OCT mounting medium and 
mounted on cryostat chucks using OCT mounting medium (ThermoFisher). Sections 
were cut using a cryostat (Leica CM1900). The sections were cut to a thickness of 10μm 
and mounted by layering on SuperFrost Plus (VWR) slides and immediately placed on 
dry ice. Sections are kept at -20oC to -80oC.  
The sections were allowed to equilibrate to RT before staining. Using a PAP hydrophobic 
marker pen (Daido Sangyo), a working area was drawn around each section. The OCT 
mounting medium (ThermoFisher) was then washed off using TBS. The sections were 
incubated in immunofluorescence blocking buffer (Table 1) for 30 min after which the 
solution was removed gently by blotting with tissue paper and the primary antibodies 
were applied. The sections were left incubating in primary antibodies overnight at 4oC in 
a damp chamber. After primary antibody incubation, the sections were washed 3 x 5 min 
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using TBS + 0.1% Tween-20. Secondary antibody was then applied and the sections 
were left incubating for 1 h. The secondary antibodies were then removed gently by 
blotting with tissue paper and DAPI applied for 10-15 min. Sections were then washed 
3x 10 min in TBS + 0.1% Tween-20 and 1x 10 min in TBS. Excess liquid was blotted off 
carefully using tissue paper and a drop of Vectashield (Vector Laboratories) was applied 
on top of the sections and a coverslip applied. The coverslip was sealed in place using 
nail varnish. All antibodies and dyes were prepared in blocking solution. 
2.4.3. Microscopy and analysis 
Images were acquired on a Nikon TE-200 microscope using a 1.45 NA 100x objective, 
Sedat quad filter set, PIFOC Z-axis focus drive (Physik Instruments) and a CoolSnapHQ 
High Speed Monochrome CCD camera (Photometrics) run by Metamorph image 
acquisition software. For deconvolution analysis, Z-stacks were acquired at intervals of 
0.2 μm from the 1 μm above to 1 μm below the imaged nucleus using the software 
AutoQuant X3. 
2.5. Protein methods 
2.5.1. Total protein extraction from mammalian cells 
Protein samples were prepared from cells after directly lysing in TRIzolTM. Cells were first 
washed with PBS. TRIzol reagent was then added and the cells scraped from the dish 
using cell scrapers. Cell suspensions were collected in 1.5 ml eppendorf tubes and 
mixed. 0.2 ml of chloroform was then added and mixed by shaking vigorously for 15-20 
s. The top phase was discarded after centrifugation at 12,000 x g for 15 min at 4oC. 
Acidified methanol acetone was then added, mixed and the solution was left at -20oC 
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overnight for the protein to precipitate. Protein pellets were collected by centrifugation at 
1,000 x g and the supernatant discarded. The protein pellets were then suspended in 
acidified methanol acetone and the centrifugation was then repeated and the pellets were 
allowed to air dry.  Once dry, the pellets were resuspended in 20 mM Tris, pH 8.0, 1% 
SDS. Acidified methanol acetone was added and the proteins were once again 
precipitated at -20oC overnight. The precipitates were then collected by centrifugation at 
1,000 x g. The air dried pellets were then resuspended in protein sample buffer (20 mM 
Tris, pH 8.0, 1% SDS with coomassie brilliant blue dye and glycerol). 
2.5.2. Western blotting 
Protein samples were separated on 8-12% Tris-glycine-SDS or Bis-Tris gels. 
Subsequently the gels were transferred onto nitrocellulose membranes (Odyssey 926-
31092) by means of semidry transfer (BIO-RAD). After transfer the membrane was 
blocked in Western blot blocking buffer (5% milk powder (w/v) in PBS/TBS with 0.05% 
Tween-20) for 30 min. Subsequently, the membrane was incubated with the primary 
antibody diluted in western blot blocking buffer at the dilutions indicated in Table 3 for 60 
min at room temperature or overnight at 4oC. Six washes in PBS/TBS, 0.05% Tween-20 
were then followed by incubation with the secondary antibody conjugated to horseradish 
peroxidase (HRP) or an IRDye® for 60 min at room temperature. After 6 washes in 
PBS/TBS, 0.05% Tween-20, the membrane was incubated with the ECL reagent 
(Amersham) to allow the HRP to react with hydrogen peroxide and luminol to generate a 
fluorescent signal that was measured on an X-Ray film (CP-BU NEW, Agfa). 
Alternatively, for Li-Cor visualisation of blots, membranes IRdye®-conjugated antibodies 
were detected on a Li-Cor Odyssey Quantitative Fluorescence Imager. 
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2.5.3. Lamin purification from inclusion bodies 
pET28-b vector containing pre-processed WT lamin A or point mutant variants were 
transformed into BL21 protein expressing bacteria. A preculture was grown overnight at 
37oC. This culture was diluted the next day and allowed to grow for 3-4 h until the culture 
reached OD 0.6 at 600 nm. Induction was carried out with 0.3 mM IPTG for 4 h at 37oC. 
Bacterial cells were then harvested via centrifugation and the pellet resuspended in lamin 
lysis buffer (Table 1). Lysis was done through sonication and DNase was used to digest 
residual DNA. Inclusion bodies were collected by centrifugation and washed with 1% 
Triton X-100. This centrifugation and wash step was repeated three times. After removing 
all Triton X-100 wash buffer, the inclusion body pellet was solubilised overnight in urea 
containing buffer (Table 1). 
2.5.4. MBP-tagged protein purification 
Plasmids carrying maltose binding protein (MBP) fusions to NET nucleoplasmic 
fragments in the pMAL-CRI vector were transformed into BL21 bacterial cells. A 
preculture was grown overnight at 37oC. This culture was diluted the next day and allowed 
to grow for 3-4 h until the culture reached OD 0.6 at 600 nm. Induction was carried out 
with 0.3 mM IPTG for 4 hours at 37oC or overnight at 18oC (for long fragments, it is 
recommended to induced for longer at lower temperatures). Bacterial cells were then 
harvested by centrifugation and the pellet resuspended in MBP lysis buffer (Table 1). 
Lysis was done through sonication and DNase was used to digest residual DNA. 
Protein fragments were then affinity purified using standard protocols set out by the 
affinity matrix manufacturer, using stated buffers or buffers listed in Table 1. Protein 
lysates were diluted in MBP column buffer (1/10) before loading onto the amylose resin. 
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Bound proteins were washed with at least 50x bed volume using the same column buffer 
before eluting using MBP elution buffer. The eluted proteins were dialyzed into TBS and 
concentrated using spin concentrator columns simultaneously in an attempt to remove 
free maltose. 
2.5.5. GST-tagged protein purification 
pGEX-4T1 vector containing nucleoplasmic fragments of NETs fused to a glutathione s 
transferase (GST) tag were transformed into BL21 protein expressing bacteria. A 
preculture was grown overnight at 37oC. This culture was diluted the next day and allow 
to grow for 3-4 hours until the culture reach OD 0.6 at 600 nm. Induction was carried out 
with 0.3 mM IPTG for 4 hours at 37oC or overnight at 18oC (for long fragments, it is 
recommended to induced for longer at lower temperatures). Bacterial cells were then 
harvested via centrifugation and the pellet resuspended in GST lysis buffer (Table 1). 
Lysis was done through sonication and DNase was used to digest residual DNA. 
Protein fragments were then affinity purified using standard protocols set out by the 
affinity matrix manufacturer using stated buffers or buffers listed in Table 1. Glutathione 
Sepharose 4B beads were packed and washed with at least 20x bed volume of PBS (pH 
7.3). Cell lysate was applied and incubated with the beads for 30 min at room 
temperature. After the lysate had been removed, the beads were washed with at least 
50x bed volume of PBS (pH 7.3). The proteins were eluted using GST elution buffer. 
2.5.6. HIS-tagged protein purification 
pET28-b vector containing nucleoplasmic fragments of NETs were transformed into BL21 
protein expressing bacteria. A preculture was grown overnight at 37oC. This culture was 
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diluted the next day and allow to grow for 3-4 hours until the culture reach OD 0.6 at 
600nm. Induction was carried out with 0.3 mM IPTG for 4 hours at 37oC. Bacterial cells 
were then harvested via centrifugation and the pellet resuspended in lamin lysis buffer 
(Table 3). Lysis was done through sonication and DNase was used to digest residual 
DNA. 
Protein fragments were then affinity purified using standard protocols set out by the 
affinity matrix manufacturer using stated buffers or buffers listed in Table 1. Nickle matrix 
was packed and washed with at least 20x bed volume of equilibration buffer. Cell lysate 
was applied and allowed to bind for at least 30 min. Bound proteins were washed with at 
least 50x bed volume of equilibration buffer before eluting using elution buffer. 
Matrix was regenerated before subsequent use using the manufacturer’s protocol (HIS-
Select Nickel Affinity Gel).  
2.5.7. Affinity purification of antibodies 
Antibodies were affinity purified against the protein fragments/peptide used in their 
generation.  
Affi-gel matrix was activated with ice cold water. The protein antibody baits were dialysed 
out of Tris containing buffer into 0.01 M NaHCO3, 0.1 M to 0.5 M NaCl before incubation 
overnight with the matrix at 4oC. Supernatant was then removed and the matrix washed 
three time with 0.01 M NaHCO3, 0.1 M to 0.5 M NaCl. The matrix was then incubated 
with 0.1 M Tris, pH 8 or with 1 M ethanolamine, pH 8 overnight at 4oC. 3 alternating 
washes were carried out with 0.1 M NaAc, 0.5 M NaCl pH 4 and 0.1 M Tris NaCl pH8. 
The matrix was then either used or stored in 0.1 M Tris, 0.5 M NaCl, pH 8, 0.02% NaN3. 
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For use, all supernatant was drained and the matrix equilibrated using PBS. Serum was 
passed over the matrix via a gravity column. PBS washes were carried out before elution. 
Elution of antibodies was done using 0.2 M glycine pH 2.8 or 4 M MgCl2. Glycine elution 
was collected on a bed of 1 M Tris pH 8.8 (50-100 l per 500 l elution). MgCl2 elution 
was dialyzed into PBS using spin concentrator columns. Elution was monitored using a 
Nanodrop 2000c measuring absorbance at 210 nm. 
Glycerol was added to a final concentration of 10-25% to the eluted antibodies to help 
with stability. Antibody solutions were concentrated using standard spin concentrators 
with the appropriate molecular cut off. 
2.5.8. Size exclusion chromatography 
Size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) 
was performed using an ӒKTA micro HPLC with a Superdex 200 10/300 GL column 
coupled with an on-line UV detector, Viscotek MALS-20 scattering detector (Malvern) and 
refractive index detector Viscotek VE3580 (Malvern). The Superdex column was 
equilibrated with buffer not containing any protein overnight (0.5 ml/min flow rate). 250 µl 
of protein samples were injected for analysis. Analysis of the mass was performed using 
the OmniSEC software package (Malvern). Sample runs and analysis were performed 
with Dr Martin Wear. 
2.6. Protein interaction methods 
2.6.1. Solid phase binding assay 
Excess HIS-Tagged lamins (>9 pM) were bound to the nickel-plated wells in 100 µl urea 
buffer for 1 h. Excess lamins were washed off using 200 µl of TBS-0.05% Tween 20 three 
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times 10 min washes. MBP-Tagged NET fragments in TBS were then added on top of 
the lamins in multiples of 9 pM (0, 20, 50, 100) and left to incubate at room temperature 
for 1 hour. The wash steps were then repeated as previous before anti-MBP antibodies 
were added onto each well and left for 1 h. Excess antibodies were then washed off. 
Alexa-488 antibodies were diluted 1/400 and 45 l was added to each well and incubated 
for 1 h. Before reading, the wells were washed 3 times with TBS-0.05% Tween-20 and 1 
time with TBS. The fluorescence signal at was read using a Modulus TM II Microplate 
Multimode Reader (Turner BioSystems) using their blue optical kit with a max excitation 
wavelength of 490 nm and emission wavelength of 510-570 nm. An absolute read out 
was taken and blanked using control empty wells on each plate. The plates used were 
96 wells nickel coated plates (Pierce 15342) 
2.6.2. Surface Plasmon Resonance (SPR) 
SPR single cycle kinetic experiments (5 injections) were performed, at 25˚C. A 2-fold 
concentration series of NETs fragments ranging from 0.3125 µM – 5 µM, in TBS, 0.05 
mM EDTA, was injected over the sensor surface bound with 70 response unit (RU) of 
immobilised His-Lamin A, at 30 µl.min-1 with 90 sec contact and dissociation times. 
The equilibrium dissociation constant was calculated from the sensorgrams by global 
fitting of a 1:1 binding model, with mass transport considerations, using analysis software 
(v2.02) provided with the Biacore T200 instrument. The experiments were carried out on 
Sensor Chip NTA (BR100034) from GE Healthcare life sciences. Lamins were bound to 
the surface in 6 M urea, 25 mM HEPES. The same urea buffer was used to dissociate 
binding between the solid phase and the soluble components. The sensor chip was 





All tissue-specific diseases require a mechanism to explain their pathology. In the case 
of EDMD, where all currently linked proteins are widely expressed, one postulate is that 
there are tissue-specific factors involved. Indeed, it seems improbable that mutations in 
the same gene can cause multiple diseases with unique aspects to their phenotype 
unless other proteins mediate the tissue-specific aspects of phenotype. LMNA is an 
example of such a gene (figure 4).  
Muscular dystrophies such as EDMD and LGMD can affect different muscles. The work 
presented in this chapter, attempts 
to identify possible differences 
between muscle sub-groups, to 
elucidate any tissue-specific 
components which may contribute 
to pathology. Antibodies to some 
NETs, identified in the Schirmer lab 
proteomic studies (Tmem38A, 
NET5, WFS1, Tmem214) were 
acquired and used in this study to 
see if they yielded expression 
and/or distribution differences 
amongst muscle subtype.  
Figure 4. Affected muscle groups in different disorders 
can be caused by mutations in the same gene. Lamin A 
has been linked to diseases affecting different muscle 
groups, sometimes with overlapping phenotype such 
as EDMD and LGMD while other times with specific 
pathology such as DCM. In brackets are some of the 
genes linked to each disease. 
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As well as antibody availability, these proteins were chosen for their relevancy to the 
existing proposed disease mechanisms. NET5 (SAMP1), Wolfram syndrome 1 (WFS1) 
and Tmem214 (FLJ20254) all exhibit association with cytoskeleton components during 
functional testing (Wilkie et al. 2011). As mentioned previously, NET5 was also shown to 
associate with TAN lines and some LINC complex members and is reported to be 
required for nuclear migration (Borrego-Pinto et al. 2012). Tmem38a (TRIC-A) is a 
muscle specific NET that is involved in Ca2+ ion regulation (Yazawa et al. 2007). 
Tmem38A is reported to form a trimeric cation channel, which is responsible for 
maintaining intracellular stores and is important for regulation of hypertension in smooth 
vascular muscles and maintaining sarcoplasmic and endoplasmic reticulum calcium 
homeostasis (Yamazaki et al. 2011, Zhou et al. 2014). NET5, Tmem38A, WFS1 and 
Tmem214 have also been shown to be involved in recruiting chromatin to the nuclear 
periphery (Robson et al. 2016, Zuleger et al. 2013). I hypothesize that these NETs may 
contribute to tissue-specific muscle disease pathology through either mechanical 
instability or genome regulation and that it may be possible to identify differences 
between tissue sub-types, by looking at normal human muscle samples as well as 




Figure 5. Muscle anatomy of the human body. Diagram showing the muscle groups present 
in the human body. Highlighted in RED are the human muscle groups obtained in this 
study, while in blue are the matched muscles obtained from mice. The diaphragm is not 





3.1. Confirming expression of NETs in muscle nuclei 
and comparison between human muscle groups 
Through collaboration with clinicians, I was able to obtain several muscle groups from 
control individuals (muscular dystrophy excluded). All muscle samples were obtained 
from several distinct sources with full ethical approval. I proceeded to stain these different 
muscle groups from both male and female samples. Dystrophin, a sarcoplasmic 
membrane marker, was used to distinguish between the nuclei of the inside and outside 
of muscle fibers. The tissues examined were bicep brachii (figure 6), vastus lateralis 
(figure 7) and gastrocnemius (figure 8). Pathology in bicep brachii is shared between 
EDMD and LGMD, with the latter affecting a broader upper arm area, while 
gastrocnemius pathology is exclusive to EDMD and vastus lateralis pathology is 
exclusive to LGMD (figure 4). 
Muscle sections were stained using antibodies raised against selected NETs. Muscle 
fibers were defined by co-staining with either dystrophin or laminin2a. Nuclei were stained 
using DAPI. Tmem38A was found to have the most specific expression pattern, residing 
exclusively in muscle fiber nuclei. Tmem38A antibodies yielded staining exclusively in 
muscle nuclei as affirmed by co-staining with dystrophin and DAPI.  In figure 6, 7 and 8 
the nuclei indicated by the asterisks have Tmem38A staining as well as being inside the 
dystrophin-marked cells, while the DAPI-stained nuclei outside these cells and do not 
stain with the Tmem38A antibodies. Staining with NET5, Tmem214 and WFS1 antibodies 
yielded ubiquitous muscle staining with positive antibody staining in nuclei inside and 
outside muscle fibers. In all three muscle groups, tested NETs were all found to stain 
nuclei inside muscle fibers. However, only Tmem38A showed exclusive fiber staining with 
NET5, Tmem214 and WFS1 present in nuclei in the surrounding connective tissues. No 
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observable differences were found to exist between muscle groups. Quantification could 
not be carried out due to the different sources and storage conditions of the samples 





Figure 6. Staining of NETs identified in the proteomic studies in Bicep Brachii. (A) Male 
control (B) Female control. (*) Tmem38A positive nuclei inside muscle fibers. (Red) 
Dystrophin staining marking plasma membrane of muscle fibers. (Green) NET staining. 




Figure 7. Staining of NETs identified in the proteomic studies in Vastus Lateralis. (A) Male 
control (B) Female control. (*) Tmem38A positive nuclei inside muscle fibers. (Red) 
Dystrophin staining marking plasma membrane of muscle fibers. (Green) NET staining. 




Figure 8. Staining of NETs identified in the proteomic studies in Gastrocnemius. (A) Male 
control (B) Female control. (*) Tmem38A positive nuclei inside muscle fibers. (Red) 
Dystrophin staining marking plasma membrane of muscle fibers. (Green) NET staining. 
(Blue) DAPI staining marking nuclei. Scale bar = 10 m 
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3.2. Comparison between mouse muscle groups 
With the difficulties in obtaining control human sections, only three human muscle groups 
were examined. To further study the postulate that tissue-specific factors are involved in 
disease pathology, the study was expanded to include mouse muscles. Five different 
muscle groups were obtained: gastrocnemius (figure 9), tibialis anteria (figure 10), 
diaphragm (figure 11), extensor digitorum longus (figure 12) and musculus soleus (figure 
13). These samples were obtained through collaboration with Heinrich Brinkmeier. The 
muscle groups obtained were matched with those present in human (figure 5). After 
sectioning, immunofluorescent staining was carried out under the conditions and using 
the same antibodies used on the human samples. Due to poor sectioning, we could not 
confirm WFS1 expression in the musculus soleus samples.  
As with the human sections, the mouse samples were stained with dystrophin (red) to 
mark the plasma membrane of muscle fibers to distinguish between the inside and 
outside. NETs staining are in green and nuclei were stained with DAPI. Tested NETs 
were present in muscle fiber nuclei in all tested muscle groups (figure 9-13). Tmem38A 
showed the same specificity as was found in the human tissues with staining absent in 
connective tissue nuclei. No observable differences were seen between the different 
muscle groups and freezing/cutting artifacts preventing quantification. 
Samples of the gastrocnemius of a muscular dystrophic (MDX) mouse were also 
acquired. This mouse line has a single substitution in exon 23 in the dystrophin gene, 
resulting in a premature stop codon (Sicinski et al. 1989, Carberry et al. 2013). To see 
whether there is any abnormality in dystrophic muscle, the same staining of the NETs 
was carried out on this MDX sample. Staining of the muscle section revealed the 
presence of all NETs with no observable difference when compared with controls (figure 
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14). Poor sectioning and freezing artifacts present meant it was not possible to confirm 
WFS1 expression. 
 
Figure 9. Staining of NETs identified in the proteomic studies in mouse Gastrocnemius. 
(Red) Dystrophin staining marking plasma membrane of muscle fibers. (Green) NET 
staining. (Blue) DAPI staining marking nuclei. Tested NETs stained positively in muscle 







Figure 10. Staining of NETs identified in the proteomic studies in mouse Tibialis Anteria. 
(Red) Dystrophin staining marking plasma membrane of muscle fibers. (Green) NET 
staining. (Blue) DAPI staining marking nuclei. Tested NETs stained positively in muscle 




Figure 11. Staining of NETs identified in the proteomic studies in mouse Diaphragm. (Red) 
Dystrophin staining marking plasma membrane of muscle fibers. (Green) NET staining. 
(Blue) DAPI staining marking nuclei. Tested NETs stained positively in muscle nuclei. Scale 




Figure 12. Staining of NETs identified in the proteomic studies in mouse Extensor 
Digitorum Longus. (Red) Dystrophin staining marking plasma membrane of muscle fibers. 
(Green) NET staining. (Blue) DAPI staining marking nuclei. Tested NETs stained positively 




Figure 13. Staining of NETs identified in the proteomic studies in mouse Musculus Soleus. 
Due to poor staining, expression and distribution of WFS1 was not confirmed. (Red) 
Dystrophin staining marking plasma membrane of muscle fibers. (Green) NET staining. 
(Blue) DAPI staining marking nuclei. Tested NETs stained positively in muscle nuclei. Scale 




Figure 14. Staining of NETs identified in the proteomic studies in a muscular dystrophic 
mouse Gastrocnemius. Due to poor staining, expression and distribution of WFS1 was not 
confirmed. (Red) Dystrophin staining marking plasma membrane of muscle fibers. (Green) 
NET staining. (Blue) DAPI staining marking nuclei. Tested NETs stained positively in 
muscle nuclei. Scale bar = 10 m 
3.3. Results summary 
In this chapter, I investigated the expression and distribution of Tmem38A, Tmem214, 
WFS1 and NET5 using immunofluorescence staining on tissue sections obtained from 
both human and mouse (human matched muscles). The presence of all four NETs was 
confirmed in muscle fiber nuclei in both species. The staining of the muscle sections did 
not reveal differences between muscle groups, and three NETs (Tmem214, WFS1 and 
NET5) were found at the NE of nuclei in the surrounding connective tissues. Tmem38A 
was found exclusively to reside at the NE of nuclei inside muscle fibers. Normal mouse 
muscles were compared to samples of dystrophic mouse gastrocnemius and found no 





Emery-Dreifuss muscular dystrophy (EDMD) typically presents in early childhood with 
slow progression, though adult onset also occurs (Bonne and Quijano-Roy 2013, Bonne 
et al. 2000). Three defining features of this disorder include early contractures of the 
elbows and Achilles’ tendons in the absence of major muscular defects, progressive 
wasting of the lower leg and upper arm muscles and cardiac conduction defects (Buckley, 
Dean, and Mahy 1999). All these features are variable in clinical presentation; while 
typical patients remain ambulatory, severe cases require wheelchairs. Likewise, cardiac 
defects do not always present, but complete heart block can occur in the most severe 
cases. Conduction defects can also present in the absence of prior muscular involvement 
(Emery 2000) and female carriers of the X-linked form can develop cardiac problems 
(Merchut, Zdonczyk, and Gujrati 1990). Even within the same family, the same mutation 
can yield highly variable clinical presentation among family members (Bonne et al. 2000, 
Mercuri et al. 2004, Rankin et al. 2008). 
With this clinical variability, it was not surprising to find that EDMD is also genetically 
variable. Mutations in eight nuclear envelope proteins account for ~47% of patients. The 
vast majority of mutations are X-linked in EMD (encoding emerin) (Bione et al. 1994) and 
autosomal dominant in LMNA (encoding lamin A and C) (Bonne et al. 1999) though more 
rare autosomal recessive LMNA mutations also occur (Raffaele Di Barletta et al. 2000). 
Lamin A is a nuclear intermediate filament protein that lines the inner surface of the 
nuclear envelope, while emerin is a nuclear envelope transmembrane protein (NET). 
Roughly 3% of patients are linked to mutations in five other NETs: TMEM43, SYNE1, 
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SYNE2, SUN1 and SUN2 (Liang et al. 2011, Meinke et al. 2014, Zhang et al. 2007). The 
remaining 3% of known mutations are linked to FHL1 (encoding Four and a half LIM 
domain 1) (Gueneau et al. 2009). FHL1 has many splice variants that have multiple 
cellular localizations including muscle z-bands and the nucleus, but FHL1B also targets 
to the nuclear envelope (Ziat et al. 2016). FHL1 is also linked to other myopathies such 
as X-linked myopathy with postural muscle atrophy (XMPMA) (Windpassinger et al. 2008) 
and deletion in mice yields to muscle hypertrophy (Sheikh et al. 2008). The strong nuclear 
envelope links for nearly half of all cases raises the possibility of a common pathway at 
the nuclear envelope affected in EDMD. 
The principal mechanisms proposed to explain how nuclear envelope disruption can yield 
pathology are genome misregulation, mechanical instability and failure of stem cell 
maintenance, all potentially leading to impaired differentiation. However, it is unclear how 
mutations in these widely-expressed proteins can cause this muscle-specific disease. 
One proposed model is that muscle-specific partners that function in complexes with 
these widely expressed nuclear envelope proteins might mediate the muscle-specific 
pathologies. Several candidates were identified by proteomics of muscle nuclear 
envelopes (Wilkie et al. 2011). WFS1, Tmem214 and Tmem38A/TRIC-A were identified 
only in muscle, out of several tissues separately analyzed by proteomics for nuclear 
envelopes (Korfali et al. 2012). NET5/SAMP1 was found in nuclear envelopes from other 
tissues, but has a muscle-specific splice variant (Zuleger et al. 2013). Several of these 
are candidates for mechanical functions due to implied connections to the cytoskeleton: 
NET5/SAMP1, WFS1 and Tmem214 localize to the mitotic spindle (Buch et al. 2009, 
Wilkie et al. 2011) and NET5/SAMP1 knockdown dissociates centrosomes from the NE 
(Buch et al. 2009). Tmem214 tracked with microtubules on the nuclear surface (Wilkie et 
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al. 2011). WFS1 also has a separate function shared by Tmem38A/TRIC-A in genome 
organization and regulation of gene expression during myogenesis (Robson et al. 2016). 
Tmem38A/TRIC-A separately contributes to the regulation of calcium ion transport (Tao 
et al. 2013, Venturi et al. 2013, Yamazaki et al. 2011, Yazawa et al. 2007). That some of 
these muscle-specific NETs had overlap in their functions further supports the possibility 
of their working in a common pathway towards EDMD pathophysiology. 
I postulate that if a central mechanism at the NE underlies EDMD disease pathology 
through disruption of a functional complex then components of that complex might 
redistribute away from the NE. Previous studies reported that emerin depends on lamin 
A for its localization to the nuclear envelope (Sullivan et al. 1999, Vaughan et al. 2001) 
and that lamin EDMD mutations similarly yield a loss of emerin at the nuclear envelope 
(Charniot et al. 2003, Raharjo et al. 2001). Additionally, the loss of nesprin localization 
with emerin EDMD mutations and corresponding loss of emerin localization with nesprin 
(SYNE) EDMD mutations was reported in muscle sections (Zhang et al. 2007). However, 
no study has comprehensively tested for the mislocalization of the wider range of EDMD-
linked proteins in a panel of patients covering the genetic spectrum of EDMD. Here a 
wide panel of EDMD muscle biopsy samples and cultured myoblasts was stained with a 
range of antibodies to the EDMD-linked proteins. To investigate potential muscle-specific 
NET involvement in disease mechanisms, the samples were also stained with antibodies 
against the muscle-specific NETs NET5/Samp1, WFS1, Tmem214 and Tmem38A. It was 
found that neither emerin nor lamin A nor any of the other NETs are uniformly altered in 
all patient samples. However, nesprin 1, SUN2, and several muscle-specific NETs 
exhibited unusual distribution patterns in a subset of samples. These findings indicate 
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that there are likely to be multiple pathways leading to EDMD pathology and suggest the 
possible involvement also of these muscle-specific NETs in the disease.  
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4.1. EDMD variants 
Emerin 
Like most nuclear envelope transmembrane proteins (NETs), most of the functions of 
emerin remain a mystery. Emerin belongs to the LEM-domain family of proteins (Lin et 
al. 2000). Members of this family directly bind barrier-to-autointegration factor (BAF) (Lee 
et al. 2001). It has been shown that this emerin-BAF interaction is important for the 
reintegration of emerin into reforming NE (Haraguchi et al. 2001). BAF has been shown 
to associate with histones and chromatin-regulatory partners (Montes de Oca, Lee, and 
Wilson 2005) (Montes de Oca et al. 2009), suggesting that this protein plays an important 
role in chromatin regulation (Segura-Totten et al. 2002) and is important in regulating cell 
fusion, an important process in myogenesis (Margalit et al. 2007). Emerin has been 
shown to bind to and regulate the activity of histone deacetylase 3 (HDAC3) a protein 
involved in chromatin silencing (Demmerle, Koch, and Holaska 2012). Interactions of 
emerin with chromatin modifying factors suggests that emerin may have important roles 
in genome organisation and regulation. Emerin has also been implicated in regulating β-
catenin activity (Markiewicz et al. 2006), suggesting a role in signalling control. Emerin 
and BAF have also been found to bind lamin A (Clements et al. 2000) (Simon and Wilson 
2013), an intermediate filament protein and core component of the nuclear lamina. A-
type lamin has been shown to be involved in many important processes such as 
chromatin organisation, gene regulation, mechanotransduction and nuclear structural 
integrity amongst others (Dechat et al. 2008). Emerin and LMNA null cultured cells 
showed increases in NE defects and mechanotransduction (Lammerding et al. 2005) 
(Lammerding et al. 2004), suggesting important roles for both lamin A and emerin in NE 
structural integrity and also mechanotransduction. Mutations in the lamin A gene have 
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been linked to many tissuespecific diseases including EDMD. The evidence presented 
so far suggests an important role of the emerin and its interaction network in EDMD 
parthenogenesis. 
FHL1 
Another X-linked gene, Four and a half LIM domain 1 (FHL1) has also been linked to 
EDMD (Gueneau et al. 2009). There are three known isoforms of the FHL1 protein and 
so far, isoform A shows high expression in skeletal and heart muscle (Lee et al. 1998). A 
high frequency of mutations are clustered around FHL1 p.C224W, which was found to be 
present in unrelated EDMD patients along with a X-linked myopathy with postural muscle 
atrophy (XMPMA) (Windpassinger et al. 2008). All mutations that are linked to EDMD are 
found in the distal region of the gene and have been found to disrupt the LIM domains or 
nuclear localisation sequence (NLS) and FHL1 shows reduced expression in affected 
individuals (Windpassinger et al. 2008). One aspect of FHL1 associated X-linked EDMD 
is that affected individuals can show postural muscle atrophy while other muscle groups 
show hypertrophy, leading to the appearance of an athletic constitution (Morris, Sewry, 
and Wehnert 2001) (Windpassinger et al. 2008). Affected individuals can also show 
hypertrophy of the heart, which could lead to hypertrophic cardiomyopathy (Gueneau et 
al. 2009). Localisation of FHL1 has recently been confirmed at the nuclear envelope and 
it has been shown to interact with emerin and lamin A (Ziat et al. 2016). However, the 
other LIM domain proteins have been extensively studied and shown to be involved in 
processes such as cytoskeletal organisation among numerous other biological pathways 




Autosomal dominant EDMD (AD-EDMD) also exists, the first gene linked to this form of 
EDMD was lamin A (Bonne et al. 1999). There are four main types of lamins, A, B1, B2 
and C, that all localise to the INM with compositional differences between cell types. The 
differences in lamin sub-type composition contribute to the relative stability of the nuclear 
lamina for each cell type (Schirmer and Gerace 2004). Apart from structural roles of 
lamins as part of the underlying nucleoskeleton, lamins have been linked to many 
functions and mutations in lamin A in particular have been linked to many diseases 
(Worman and Bonne 2007). Lamin A linked AD-EDMD is more clinically variable than its 
X-linked cousins with variations in severity and pathology within families (Bonne et al. 
2000) (Morris, Sewry, and Wehnert 2001). Many tested NETs have been shown to 
interact with lamins either directly or indirectly. Given its many functions and interaction 
partners, it is likely that lamins and NETs form a large network at the NE and disruptions 
to this network can lead to pathology and the variations seen in EDMD. A rare lamin A 
associated autosomal recessive case of EDMD (AR-EDMD) has also been reported 
(Raffaele Di Barletta et al. 2000). 
LINC complex (nesprins and SUN proteins) 
Another important set of mutated proteins linked to EDMD are proteins of the Linker of 
nucleoskeleton complex (LINC). This complex consists of the core proteins nesprin 1, 
nesprin 2 SUN1 and SUN2. Components of the LINC complex have been proven to 
reside at the NE, nesprins to the outer nuclear membrane (ONM) and SUNs to the INM 
(Zhang et al. 2001) (Crisp et al. 2006) (Hodzic et al. 2004). The role of the LINC complex 
in connecting the nucleoskeleton network with the cytoskeleton is well characterised 
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(Meinke and Schirmer 2015). It has been shown that nesprin 1 and 2 associate with 
EDMD linked proteins lamin A and emerin (Mislow, Holaska, et al. 2002) (Zhang et al. 
2005). Along with interacting with already linked proteins, mutations in both the nesprin 
and SUN proteins have been linked to EDMD (Zhang et al. 2007) (Meinke et al. 2014). 
Cultured primary cells from LINC complex deficient patients often show defects in NE 
morphology and impaired association with binding partners. Mutations in nesprins have 
all been found in the lamin/emerin binding domain. The data suggests that structural 
integrity of the NE plays an important role in disease pathology and that perturbation of 
the interactions between the LINC complex, proteins of the NE, nuclear lamina emerin 
and lamins may cause EDMD.  
Tmem43 
Recent patient analysis revealed Tmem43/LUMA, a NET identified to reside at the INM 
(Dreger et al. 2001) is linked to a EDMD-related myopathy (Liang et al. 2011). The index 
patient (p.Glu85Lys) was diagnosed with EDMD, muscle pathology revealed fiber size 
variations as well as internal nuclei. Patient 2 was reported to have slow progressive 
proximal muscle weakness requiring a pacemaker transplant at 64 years, due to atrial 
fibrillation with bradycardia. Immunohistochemistry revealed normal positive staining for 
emerin among other markers. It is reported that LUMA can form homo-oligomers and the 
reported mutation (p.Glu85Lys) disrupts this oligomerization. Co-immunoprecipitation 
assay carried out by the same group showed interactions with emerin and SUN2, but not 
SUN1. They also reported no marked differences between binding to WT and mutant 
LUMA (Liang et al. 2011). The same report also found that over-expression of mutant 
LUMA disrupts NE morphology and forms extranuclear aggregates (Liang et al. 2011). 
Additionally, it was found that emerin and SUN2 showed decreased staining at the NE 
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with emerin mislocalisation to the ER (Liang et al. 2011). Electroporation of mouse Tibialis 
Anteria muscle with mutant LUMA showed the same decrease in emerin and SUN2. 
LUMA disruption of linked NE protein in patients suggests pathology may arise due to 
disruption of protein complexes. 
Other 
More recently, mutation resulting in the loss of expression of another NE protein LAP1β 
in skeletal muscle nuclei, was reported in the case of a patient with muscle weakness 
and atrophy with contractures, rigid spine and cardiac defects (Kayman-Kurekci et al. 
2014). LAP1β is an INM protein which has been shown to bind lamins directly (Senior 
and Gerace 1988) (Foisner and Gerace 1993) and it also interacts with emerin (Shin, 
Mendez-Lopez, et al. 2013). LAP1 appears to have higher expression in mouse striated 
muscle than in human striated muscle, a pattern that is opposite to emerin. Also unlike 
emerin, a conditional LAP1β knockout mice showed a muscular dystrophy phenotype 
(Shin, Mendez-Lopez, et al. 2013). Expression patterns in mice and the loss of 
expression in muscular dystrophic patients suggests that LAP1β potentially has 
overlapping functions with emerin and may cause disease phenotypes in much the same 
way. Although not currently classified as EDMD due to the lack of elbow contractures, we 
should keep an open mind as the case of LAP1β may be a new variant of EDMD not yet 
seen before.  
4.2. EDMD mechanisms 
With potentially 8 NE/nuclear lamina proteins linked to the disease, there is no doubt that 
EDMD is a disorder of the NE. It is still unclear how seemingly widely expressed protein 
cause tissue-specific diseases such as EDMD, but separately from this question is the 
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more fundamental question of how NE defects can yield pathology. Current mechanisms 
proposed to try and explain the pathology of these diseases include altered gene 
regulation, mechanical stress and failure of stem cell maintenance. Indeed, there is much 
evidence supporting all of these mechanisms. Extensive roles of NETs in genome 
organisation and the binding and regulation of transcriptional regulators would be 
consistent with the assumption that disruption of such regulatory interactions could lead 
to impairment of differentiation pathways, ultimately leading to muscle loss after damage. 
Studies have found NE deformation associated with LMNA and emerin mutations 
(Lammerding et al. 2004) (Lammerding and Lee 2005) (Lammerding et al. 2005, Lee et 
al. 2007, Broers et al. 2005, De Vos et al. 2010, De Vos et al. 2011, Houben et al. 2009). 
Defects in how cells deal with mechanical stress could lead to inability of muscle to repair 
damage caused by use. Failure of stem cell maintenance could also help explain muscle 
loss, as if the population of muscle satellite cells are depleted then muscles would lose 
their ability to replace damaged fibres. While these mechanisms may explain some of the 
pathways to pathology, none of the mechanisms proposed so far can fully explain the 
tissue-specificity of NE linked diseases and it is likely that a combination of mechanisms 
are required for a disease phenotype. 
Although we’ve begun to understand the interconnectivity of the nuclear envelope and its 
protein complement (figure 15), there is much still unknown to us. It is postulated that 
tissue-specificity is conferred by interactions between the known linked NE proteins and 
as yet unidentified tissue-specific proteins that reside at or interact with the NE. Proteomic 
studies have found a subset of tissue-specific NETs (Schirmer et al. 2005) (Wilkie et al. 
2011) (Korfali et al. 2012) which could potentially add to our understanding of the 
specificity of phenotypes in diseases such as EDMD. Indeed, studies on these new NETs 
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have found them to have functions in genome organisation, cell cycle control and 
differentiation (Zuleger et al. 2013) (Malik et al. 2014) (Batrakou et al. 2015). Functional 
screens carried out on these NETs also revealed other NETs that have associations with 
structural components of the cell. In particular, NET5/SAMP1 has been shown to be an 
INM protein which localises to the mitotic spindle poles, and knockdown of NET5/SAMP1 
was shown to increase the distance between the centrosomes and the NE (Buch et al. 
2009) (Figueroa et al. 2010). NET5/SAMP1 has also been shown to interact with some 
of the LINC complex components along with emerin and lamin A (Gudise et al. 2011) 
(Jafferali et al. 2014). On top of these findings, NET5/SAMP1 has also been found to 
associate with TAN lines, playing an important role in nuclear migration (Borrego-Pinto 
et al. 2012). These associations with linked components of EDMD suggest NET5/SAMP1 
could play a role in disease pathology through the mechanical stability mechanism. Also, 
identified in the functional screens were three other proteins with apparent cytoskeleton 
associations, namely Tmem70, Tmem214 and WFS1. Apart from cytoskeletal 
associations and genome organisation functions, tissue-specific NETs have also been 
found to be involved in signalling. Tmem38A/TRIC-A, a muscle specific NET is reported 
to form cation channels transporting calcium (Yazawa et al. 2007) (Yamazaki et al. 2011) 
(Venturi et al. 2013) (Tao et al. 2013) (Zhou et al. 2014). Signalling is important in muscle 
function and defective muscle function may lead to disease pathology.  
Finding new or similar functions of these NETs to existing linked NE proteins suggests 
that as a tissue-specific component of the network, they could potentially contribute to 
pathology via the mechanisms mentioned above. As all proteins linked to EDMD have 
been shown to interact with each other, albeit separately, a postulate is that linked 
proteins and tissue-specific NETs interact in a large network with the tissue-specificity 
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explained by interaction with new novel NETs. About 50% of EDMD cases are linked to 
8 NE proteins described in section 4.1. This leaves a large number of patients with EDMD 
and no linked cause that could be due to mutations in these muscle-specific proteins with 
functions linked to the postulated mechanisms for EDMD disease pathology. To further 
study the involvement of existing and new NETs (NET5/SAMP1, Tmem38A, Tmem70, 
Tmem214, WFS1), presented here is panel screen of nine EDMD patients, looking at 
linked (already found to cause disease) and unlinked (no diseases associated) NETs and 
their expression pattern in different stages of muscle development as well as different 
cell type and also potential interactions between novel NETs and existing NE proteins. I 
postulate that if other NETs mediate tissue-specific pathology, they might be disrupted in 
their distribution in patients. 
 
Figure 15. The current known network of the cell. (Figure taken from (Kaminski, Fedorchak, 
and Lammerding 2014)) 
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4.3. Distribution of EDMD-linked proteins in cultured 
patient muscle cells 
Several earlier reports presented data showing that emerin, nesprins and lamin A/C 
staining, normally concentrated at the nuclear envelope, was aberrant in cells expressing 
EDMD mutations (Raharjo et al. 2001, Sullivan et al. 1999, Vaughan et al. 2001, Zhang 
et al. 2007). However, typically only a single patient mutation was tested and only lamin 
A/C and a few NETs were tested for any given sample, though EDMD has now been 
linked to eight different nuclear envelope proteins. To determine if any particular one of 
these proteins is recurrently defective in its intracellular distribution, a panel of three 
control and eight EDMD patient myoblasts (Table 12) were stained for emerin, lamin A/C, 
nesprin 1, nesprin 2, SUN1, SUN2, and FHL1. All stainings were done in parallel and all 
images were taken with the same exposure times and microscope software settings. The 
samples in table 12 were obtained from CNDB (Centre for Neuromuscular Disorders 




Table 12. Patient and control myoblast/fibroblast cultures used in this study 
 Type Gender Age at biopsy  Source 
C1 Control Female 36 MTCC 
C2 Control Male 35 MTCC 
C3 Control Male 5yrs CNDB 
P1 FHL1 Male 51 MTCC 
P2 LMNA p.R453W Female 12 MTCC 
P3 EMD p.Y59* Female 17 MTCC 
P4 LMNA p.R545C Male 18 MTCC 
P5 Unknown Male In teens MTCC 
P6 LMNA p.T582K Male 2yrs CNDB 
P7 LMNA p.E358K Female 2yrs CNDB 
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This panel included patients with lamin A/C-linked (P2, 4, 6 and 7), emerin-linked (P3), 
and FHL1-linked (P1) disease (table 12). Surprisingly, emerin, despite previous reports 
of its aberrant distribution, exhibited strong nuclear envelope staining, with a crisp rim of 
fluorescence at the nuclear perimeter (nuclear rim) in all patient cells and was 
indistinguishable from the control cells (Fig. 16). Patient P3 was a female with a 
heterozygous truncation mutation (p.Y59*) in the X chromosomal gene encoding emerin. 
This patient atypically had a muscle phenotype, but expressed full-length emerin in a 
subset of cells, likely indicating an additional unknown mutation (Meinke et al. 2015). 
Here this subset of emerin-positive cells exhibited a moderately weaker staining 
compared to other patients. While some emerin accumulation in the ER appeared in 
patients P2 and P5, it was not more than for control C2, and this control had more ER 
accumulation than other EDMD patient cells. Thus, any minor differences in emerin 






Figure 16. Staining of control (A) and patient (B) myoblasts with antibodies to EDMD-linked 
proteins. The patient and control descriptions are given in Table 13 and the antibodies used 
are described in Table 14. Most nuclear envelope proteins gave strong crisp nuclear rim 
staining in both control and patient groups. Though some EDMD-linked patient cells 
exhibited partial mislocalisation, no linked proteins exhibited uniform mislocalisations in 
the wide range of patient mutations investigated. The nesprin 2 antibodies do not stain well 
in the myoblast/fibroblast cultures; so, these were retested on differentiated cells in Figure 
15. Widefield images are shown. Scale bar, 10 µm. 
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No visible differences were observed for lamin A/C staining between the patient and 
control cells and even within each set, unlike emerin where both some control and some 
patient cells exhibited minimal ER accumulation (Fig. 16). The image selected for control 
C3 was chosen because the cell was smaller, likely due to being at an earlier cell cycle 
stage, and characteristically a larger nucleoplasmic lamin pool is present before the 
lamina is fully reassembled and nuclear volume increases after mitosis. None of the 
larger or smaller cells from the patients had more nucleoplasmic lamin accumulation than 
this control, further underscoring the fact that any minor visible differences can be 
discounted.  
For the other NETs and FHL1 there was greater variation amongst samples, but in nearly 
all cases a similar range of variation was observed for the controls (Fig. 16). For example, 
in multiple controls nesprin 1 staining was variable in intensity at the nuclear membrane 
compared to the nucleoplasm (presumably representing out of focus light from the top 
and bottom of the nucleus). Roughly half of the control cells also exhibited some punctate 
staining in the nucleoplasm, most likely due to invaginations, but possibly also soluble 
splice variants (the antibody used, MANES1E(8C3), was generated to full-length 
nesprin1-). Within the patient population similar variation was observed in overall 
intensity, relative rim intensity and punctate areas. However, patients P3 and P4 exhibited 
minor staining in the ER that was not observed for either the controls or the other patients. 
Although this is a different specific mutation, the P3 staining is consistent with the 
previous report of nesprin mislocalization with an emerin EDMD mutation (Zhang et al. 
2007). This is a new observation for the P4 LMNA p.R545C mutation, but notably other 
lamin and the FHL1 mutant myoblasts did not exhibit similar ER accumulations; thus, this 
difference is not a general characteristic of EDMD. SUN2 also exhibited some ER 
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accumulation in myoblasts from two patients, but these were different patients with lamin 
mutations (LMNA p.T528K and LMNA p.E358K) and some ER accumulation was also 
observed in the control myoblasts. In general, SUN2 and FHL1 exhibited the most 
variable staining patterns, but as variability was also observed in the controls this may 
reflect effects of the cell cycle or differentiation state. 
This latter issue of differentiation state is likely the reason for the poor staining of nesprin 
2, which is stained well by this antibody in differentiated myofibers (Duong et al. 2014). 
Notably, the one patient with clear rim staining, P6 (LMNA p.T528K), had the appearance 
of multiple nuclei lined up in a myotube, while the weak rim staining for P7 (LMNA 
p.E358K) appears to reflect a senescent cell by its extremely large nucleus and spread 
cytoplasm. Therefore, nesprin 2 was also stained for after induction of differentiation in 
reduced serum differentiation medium (Fig. 17). Not all patient cells differentiated 
efficiently into fused myotubes, perhaps due to myoblast passage number in culture or 
different amounts of contaminating fibroblasts. Nonetheless, a distinct rim-staining 





Figure 17. Staining of myoblast/fibroblast cultures and differentiated myotubes with 
nesprin antibodies. A: To determine whether intranuclear spots staining with nesprin 
antibodies reflected invaginations of the nuclear envelope as opposed to possible 
degradation/cleavage products, z-series images of cells stained with nesprin 1 antibodies 
were taken every 0.2 µm. In the images shown the arrows and asterisk point to different 
intranuclear spots that can be traced through the different focal planes to invaginations 
from the nuclear membrane. B: Staining after induction of differentiation into myotubes for 
nesprin 2. Large multinucleated myotubes were not obtained from all patients; however, 
changes in morphology such as elongating of the cell body or much larger cells indicative 
of cell cycle withdrawal were generally evident and rim staining could be readily observed 
compared to the very poor rim staining in the myoblast/fibroblast cultures stained in Figure 
14. Multiple images for each patient are shown to show the variability between cells. 
Widefield images are shown. Scale bar, 10 µm. 
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4.4. Distribution of muscle-specific NETs in cultured 
EDMD patient myotubes 
As the EDMD-linked NETs are all widely expressed and known to have many binding 
partners, their failure to exhibit aberrant distribution patterns uniformly through the set of 
patient samples might reflect redundancy in the partners to retain them at the nuclear 
membrane. As mutations in widely expressed nuclear envelope proteins cause a much 
wider range of tissue-specific diseases including also lipodystrophy, dermopathy, 
neuropathies and bone disorders, it has been proposed that tissue-specific binding 
partners might mediate the tissue-specific pathologies (Worman and Schirmer 2015). 
Therefore, muscle-specific partners might contribute to disease pathology, have fewer 
binding sites and be more likely to be disrupted in their distribution in patients.  
Antibodies were obtained for Tmem38A, NET5/Samp1, Tmem214 and WFS1 and tested 
for their specificity. C2C12 cells were transduced with lentiviruses encoding GFP fusions 
to these NETs, fixed, and stained with the NET antibodies. In all cases the GFP-signal 
co-localized with the NET antibody signal (Fig. 18A). Notably, for NET5/Samp1 and 
WFS1 the endogenous rim staining was sufficiently stronger than the GFP-fusions that 
an even more pronounced rim was observed in the antibody stained sample than for the 
GFP signal. The antibodies were also tested by Western blot from lysates generated from 
additional cells from the same transfections (Fig. 18B). In all cases the band recognized 
by GFP antibodies for the muscle NET-GFP fusion was also recognized by the muscle 






Figure 18. Testing of antibodies for muscle NETs. C2C12 cells were transduced with GFP 
fusions to the NETs or GFP alone and these cells were divided into two populations. A: The 
first was used to check for co-localisation between the antibody and GFP signal for the 
expressed protein. The GFP signal and NET and GFP antibody signals overlapped in all 
cases. The antibodies used in the antibody column match the GFP fusion proteins being 
expressed that are labeled on the left hand side. In the case of WFS1 as the GFP signal 
around the nuclear rim was weaker evidently than the endogenous protein staining with 
the antibody a box at the rim is enlarged so that the clear co-localisation can be seen. 
Widefield images shown. Scale bar, 10 µm. B: The second population was used to generate 
lysates to test by Western blot. The expected size for GFP-NET fusion bands is marked by 
asterisks and it can be observed that the same expressed protein fused to GFP is 
recognised by both the GFP and muscle NET antibodies. Histone H3 (lower panel) was used 
as a loading control. C: Because there is often species cross-reactivity and extra bands 
from degradation products of overexpressed proteins, the antibodies were also used to 
stain a lysate from a control human muscle biopsy. This indicated that the Tmem38A, NET5 
and WFS1 antibodies are quite specific so that any protein redistribution observed in 
immunofluorescence experiments should be specific to the NET. Tmem214 stained 
additional lower molecular weight bands that might be degradation products, but could 
also indicate cross-reactivity with other proteins. Therefore, immunofluorescence 
experiments with this last antibody should be interpreted with caution.
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Tmem38A and WFS1 are induced during muscle differentiation (Robson et al. 2016) and 
a muscle-specific isoform of NET5/Samp1 has been reported (Zuleger et al. 2013). 
Therefore, patient myoblast cultures were induced to differentiate into myotubes for 
staining. These cells were co-stained with myosin (type 2) (Fig. 19) or PCM1 (data not 
shown) as markers for differentiation to distinguish cells that may have poorly 
differentiated due to the EDMD mutation and contaminating fibroblasts (Fig. 19). The 
necessity of performing this analysis in differentiated cells was highlighted in all cases by 
the lack of rim staining in cells lacking the red myosin (type 2) signal. A clear rim with 
some punctate areas inside the nucleus was observed in the C3 control for the Tmem38A 
antibody. Similar staining was observed for P5, but a significant loss of rim staining and 
strong increase in the punctate areas was visually clear for the other lamin and emerin 
mutations (Fig. 19, upper left panels).  
NET5/SAMP1 exhibited clear nuclear rim staining in all differentiated cells for both the 
control and EDMD patient myotubes; however, a visible relative increase in ER staining 
was observed for the P5 and P3 patient samples (Fig. 19, upper right panels). For 
Tmem214 a weak rim could be discerned in all samples except for EDMD patient sample 
P4, while no WFS1 rim could be discerned in EDMD patient sample P5, though much 
stronger ER staining was observed for patients P6 and P4. Thus, none of the muscle-
specific NETs yielded a uniform redistribution phenotype in all patient samples; however, 





Figure 19. Staining of muscle NETs in patient myoblast/fibroblast cultures where myoblasts 
were induced to differentiate into myotubes. Antibodies to the muscle NETs listed were 
used to stain the control and patient cells listed. The cells were co-stained with myosin 
(type 2), a later differentiation marker, to identify cells that had differentiated within the 
population. Several EDMD patient cells exhibited more ER signal for the NETs compared 
with the control cells. Widefield images are shown. Scale bar, 10 µm. 
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4.5. Distribution of muscle-specific NETs in EDMD 
patient skeletal muscle sections 
As there are many random aspects of cultured cell growth including differing passage 
numbers from patient myoblasts and thus progress towards senescence, EDMD patients 
skeletal muscle biopsies from CIND (Centre for Inherited Neuromuscular Diseases) and 
CNDB (Centre for Neuromuscular Disorder Biobank) were used to confirm these results 
(Table 13). As muscle sections contain other cell types, these were co-stained for 
dystrophin to delineate the plasma membrane of muscle cells. All images were taken at 
the same microscope settings. For Tmem38A the controls C4 and C5 exhibited crisp 
nuclear rim staining with weaker distribution through the sarcoplasmic reticulum (Fig. 20, 
left top two panels). Crisp nuclear rim staining could be observed in all patient sections 
(Fig. 20, left lower panels). However, the relative intensity of nuclear rim to sarcoplasmic 
reticulum staining was notably diminished compared to the controls. Unlike differences in 
the cultured cells that were patient-mutation specific, this difference was observed 
generally.  
For Tmem214 a nuclear rim stain could be observed in all samples, both control and 
patient; however, this time differences in the relative and absolute intensities varied 
between patient samples so that no generalized difference could be observed. Notably, 
the nuclear rim staining for this NET was much more crisp and clear than in the cultured 
myotubes. In patients P6 and P9, a nucleus for a cell in the space between the myofibers 
as delineated by dystrophin staining, possibly a capillary nucleus (Fig. 20, red), had a 
much stronger nuclear rim staining than the nuclei in the muscle fibers. This was in 




NET5/SAMP1 stained the control nuclei very strongly against a weak background in the 
sarcoplasmic reticulum and this was the same for most patients. Moreover, some staining 
could be observed at the plasma membrane co-localized with the dystrophin membrane 
marker in the controls and most patients, but this was not present in patients P6 and P7. 
Finally, WFS1 exhibited weak staining at both the nuclear rim and sarcoplasmic reticulum 
in all fibres. Taking all images using the same settings the intensity of staining varied 
much more than for other muscle NETs, but this could reflect accessibility in the different 
sections, as when the intensity of staining was equalized in the enlarged region boxes 
the character of staining was quite similar between patients. Thus in summary, Tmem38A 
generally appeared to have more accumulation in the sarcoplasmic reticulum in all the 
patients and both Tmem214 and NET5/SAMP1 appeared to exhibit some differences 
from the controls in different subsets of patients. 
Table 13. Tissue sections used in this study 
 Type Gender Age at biopsy Source 
C4 Control Female 14 yrs CIND, 
Oswestry 
C5 Control Male 3yrs CNDB 
P6 LMNA p.T582K Male 10yrs CNDB 
P7 LMNA p.E358K Female 2yrs CNDB 
P8 LMNA p.E31del Female 2yrs CNDB 
P9 LMNA de novo in 
exon 3 








Figure 20. Muscle NET antibody staining in patient skeletal muscle sections. C4 and C5 are 
controls. The patient mutations are listed in Table 13. All sections were stained with muscle 
NET antibodies in parallel and images were taken using identical settings. DNA staining for 
nuclei is shown in blue, the muscle NET in green, and Dystrophin staining is shown in red 
to delineate the sarcolemmal nuclei of myofibers from those of nerves and the vasculature. 
Asterisks mark the nuclei that are enlarged in the lower right boxes. Note that the levels 
are adjusted on these nuclei so the intensities are similar and they can be compared for 
general characteristics. A: Tmem38A and Tmem214 antibodies. B: NET5/Samp1 and WFS1 
antibodies. Tmem38A and NET5/Samp1 distribution and intensity were much more uniform 




Table 14.Primary antibodies used in this study 








Mouse 1:50 N/A 200 kDa Sigma (M1570) clone My-
32 
Lamin A/C Rabbit 1:50 1:1000 70 kDa Schirmer et al, 2001 (3262) 
Tmem38A Rabbit 1:50 1:200 30 kDa Millipore (06-1005) 
WFS1 Rabbit 1:50 1:200 100 kDa Proteintech (11558-1-AP) 
Tmem214 Rabbit 1:50 1:200 70 kDa Proteintech (20125-1-AP) 
NET5 Rabbit 1:20 1:100 70 kDa Millipore (06-1013) 
Dystrophin Mouse 1:50 N/A 271 kDa Glenn Morris (MANDYS1 
(3B7)) 
Emerin Mouse 1:50 N/A 29 kDa Glenn Morris (MANEM1 
(5D10)) 
Nesprin1 Mouse 1:50 N/A N/A Glenn Morris (MANNES1E 
(8C3)) 
Nesprin2 Mouse 1:50 N/A N/A Glenn Morris (MANNES2A 
(11A3)) 
Lamin A/C Mouse 1:50 N/A 70 kDa Glenn Morris (MANLAC1 
(4A7)) 
SUN1 Rabbit 1:50 N/A N/A Atlas antibodies 
(HPA008346) 
SUN2 Rabbit 1:50 N/A N/A Millipore (06-1038) 
FHL1 Rabbit 1:50 N/A 32 kDa Aviva Systems Biology 
(ARP34378_T100) 
GFP Rabbit N/A 1:200 25 kDa Generated in Schirmer Lab 
to whole protein 
GFP Mouse N/A 1:1000 25 kDa Clontech (632381) 




4.6. Results summary 
These results indicate that the previous finding of emerin redistributing away from the 
nuclear envelope with lamin A mutations (Charniot et al. 2003, Raharjo et al. 2001, 
Sullivan et al. 1999, Vaughan et al. 2001) is not a general characteristic of AD-EDMD. 
Only a few patients had been tested for this before, but by comparing a wider panel of 
EDMD mutations it is now clear that the emerin redistribution effects are only 
characteristic of those few mutations. Notably, the use of 3 separate controls revealed 
that to some extent emerin redistribution can occur even in the absence of disease. Thus, 
the relevance of this redistribution to EDMD pathology is unclear even in the patients 
where it was observed. One recent study suggested a link between emerin cytoplasmic 
accumulation and pathology in that emerin-p.P183T assembles into oligomers that 
perhaps cannot pass through the peripheral channels of the nuclear pore complexes 
(Herrada et al. 2015). Nonetheless, emerin mutations result in a loss of protein. 
While the specific mutations analysed in this study and earlier studies differed, another 
aspect that may have contributed to redistribution phenotypes previously reported is the 
use of complete knockout or mutant over-expression and the use of rapidly dividing 
cancer cell lines. Two of the earlier studies focused on lamin knockout or loss (Sullivan 
et al. 1999, Vaughan et al. 2001), but most lamin EDMD mutations are dominant, total 
lamin levels generally appear normal where tested, and the point mutations by prediction 
should not block targeting and integration into the lamin polymer. The lamin mutations 
analysed here included mutations in the N-terminus (p.N31del), the rod (exon 3, 
p.E358K), the Ig fold (p.R453W), the edge of the Ig fold (p.R545C) and the unstructured 
region after the Ig fold (p.T582K). These should all yield different effects on the protein. 
Lacking the rod domain, the N-terminal deletion should act like a null, though it might 
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dominant-negatively interfere with head-to-tail assembly. The rod p.E358K mutation has 
yielded conflicting results in assembly studies with one reporting no disruption of 
filaments and the other reporting deficient assembly in vitro, more soluble protein in the 
nucleoplasm and reduced mechanical stability (Wiesel et al. 2008, Zwerger et al. 2013). 
In contrast the Ig fold mutation is on the surface, but with the backbone buried so that it 
should still enable the beta sheet, that it is a part of, to form, but push it out relative to the 
adjacent beta sheet. p.R545C is in a basic patch and so might change charged 
interactions and p.T582K is hard to predict as it is in an unstructured region.  
Other studies showing redistribution used mutant over-expression in tissue culture cells 
(Charniot et al. 2003, Raharjo et al. 2001), which may have influenced results. In these 
cases, the cells used were MEFs, lymphoblastoid cell lines and standard cancer cell lines 
as opposed to the myoblasts, myotubes and patient muscle tissue sections used here. In 
the study where emerin and nesprin were found to affect the localization of each other’s 
(Zhang et al. 2007) patient cells and muscle sections were used. However, this study 
only compared nesprin and emerin and analysed a patient with a strong combination of 
nesprin 1 and 2 (SYNE1 and SYNE2) mutations. Nonetheless, in keeping with their 
results, more intense relative nesprin 1 staining in the ER in the patient with an emerin 
mutation was found. However, for the EDMD-linked proteins, none exhibited a consistent 
redistribution phenotype throughout the wider collection of patient mutations analysed 
here and only nesprin 1 and SUN2 yielded phenotypes in subsets of patients that were 
stronger than the range of phenotypes observed when also considering a wider panel of 
three controls. 
It is also noteworthy that many of the reports using over-expressed mutant proteins in 
cancer cell lines or dermal fibroblasts in culture highlighted defects in nuclear morphology 
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and blebbing. In contrast, here using patient myoblasts and myotubes at relatively early 
passage number and skeletal muscle sections, very little nuclear morphology defects or 
blebbing were observed. This argues that aspects of 2-dimensional tissue culture, rapidly 
dividing cancer cell lines and senescence of dermal fibroblasts probably underlie these 
phenotypes. Such changes, particularly senescence, could also have influenced previous 
reports of aberrant distribution of EDMD-linked proteins. 
While notable shared differences for any of the EDMD-linked proteins were not observed, 
many differences for the muscle-specific NETs in myotubes were found. In tissue culture 
these tended, like the nesprin 1 and SUN2 effects, to be observed only in distinct subsets 
of patient cells. The redistribution of Tmem38A to the sarcoplasmic reticulum was 
observed in all but one of the patient in vitro differentiated myotubes and was observed 
in all patient skeletal muscle tissue sections, though it was not sufficiently striking to be 
used effectively diagnostically. Differences were also observed in both in vitro 
differentiated myotubes and muscle tissue sections for Tmem214 and NET5/SAMP1, 
though as for nesprin 1 and SUN2 these were only observed in subsets of patients.  
NET5/SAMP1 is particularly interesting because it also interacts with lamin B1 and SUN1 
(Jafferali, Figueroa, and Hallberg 2016) and its mutation affects the distribution of SUN1, 
emerin and lamin A/C (Gudise et al. 2011). SAMP1 also associates with TAN-lines that 
are important for nuclear migration (Borrego-Pinto et al. 2012). This provides it with a 
function that could underlie disease pathology and a molecular network that parallels that 
of the nesprins (Mislow, Kim, et al. 2002, Zhang et al. 2005). WFS1 and Tmem38A are 
also interesting because they are important for proper muscle gene expression and for 
muscle differentiation (Robson et al. 2016). In fact, disruption of three muscle-specific 
NETs participating in this function together almost completely blocked myogenesis, 
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though knockdown of each alone had little effect (Robson et al. 2016). Thus, these NETs 
are prime candidates to mediate EDMD pathology, because muscles appear to develop 
normally and then exhibit defects when they begin to be more heavily used i.e. gene 
expression defects that prevent the muscle from fully functioning make for a reasonable 
explanation of pathophysiology. Tmem38A could also influence Ca2+ regulation (Tao et 
al. 2013, Venturi et al. 2013, Yamazaki et al. 2011, Yazawa et al. 2007), especially 
considering its relative increase in the sarcoplasmic reticulum. Though much still needs 
to be done to prove their participation in EDMD pathophysiology, the finding of stronger 
redistribution effects for these muscle-specific NETs across a panel of EDMD patient 
mutations than for the already linked proteins raises the strong possibility of their 
involvement as new players in EDMD. 
Taken together this shows that the clinical variability of EDMD is also mirrored on a 
cellular level. Several different proteins at the NE can be affected to varying degrees, yet 
many of them exhibit interactions that suggest their co-functioning in a larger network. In 
addition to WFS1 and Tmem38A co-functioning in myogenic genome regulation and the 
NET5/SAMP1 partners, redundancy of functions is observed for emerin and MAN1 and 
for SUN1 and SUN2 (Crisp et al. 2006, Liu et al. 2003). This study shows that several 
different NETs can be affected to varying degrees in EDMD muscle and further clarifies 
EDMD as a NE disease, indicating that many different pathways to disrupt NE 





Tissue-specific NETs interactions 
with lamin A 
Introduction 
Lamin A has been linked to many distinct diseases (Worman and Bonne 2007), while the 
underlying cause(s) are still unknown. Lamins form the structural meshwork of the 
nuclear lamina, which is present in all cell types, except for erythrocytes that become 
enucleated during differentiation. How then does this ubiquitously expressed protein lead 
to tissue-specific pathology? One hypothesis is that a complex of proteins work together 
to define lamin functions and therefore disruption of these complexes is the real cause of 
tissue-specific disorders. This is an attractive hypothesis as many NETs have also been 
linked to diseases (reviewed in (Worman and Bonne 2007, Worman, Ostlund, and Wang 
2010)). However, these NETs are also widely expressed and therefore cannot explain 
tissue-specificity.  
Previous work carried out by the Schirmer lab identified a host of tissue-specific NETs 
(Korfali et al. 2012, Korfali et al. 2010, Schirmer et al. 2005, Wilkie et al. 2011). The 
discovery of differences in the proteome of nuclear envelope subsets gave rise to the 
postulate that one of these tissue-specific NETs interacts with lamin A to give pathology.  
Until now, only a small subset of principally known, ubiquitous NETs have been tested to 
interact with lamins (reviewed in (Gruenbaum and Foisner 2015)). In this chapter, I test 
tissue-specific NETs for their ability to bind lamins and whether this binding is reduced 
for a variety of lamin mutants linked to disease. I show that the fat-specific NET 
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Tmem120A has a statistically significant reduced binding activity to lipodystrophic 
mutants of lamin A when compared to wild type (WT) while the muscle-specific NET 
Tmem38A has reduced (not statistically strong, but consistent) binding to muscular 
dystrophy mutants of lamin A compared to WT. This chapter will also highlight some of 
the difficulties in working with full length lamins and transmembrane proteins.  
5.1. Lamin functions 
Lamins form the structural components of the nuclear lamina, the underlying meshwork 
of the nucleus, which contributes to its flexibility and stiffness. This is very important in 
cell migration as nuclear stiffness is the rate-limiting factor. Too much lamin and the nuclei 
will be too stiff and present a blocking factor when navigating small pores (Rowat et al. 
2013). Too little lamins and the nucleus will be too fragile and prone to disruption 
(Davidson and Lammerding 2014, Lammerding and Lee 2005, Lammerding et al. 2004). 
As mentioned previously, nuclear shape is frequently used as a hallmark of disease. The 
lamina has important roles in mechanotransduction via the LINC complex proteins, which 
has been indicated to affect lamins expression (Swift et al. 2013). The amount of different 
lamin subtypes present is also directly linked to differentiation. The correct levels of 
lamins are required for specific lineage; stiffer tissues generally require more lamins while 
softer tissues require less. High levels of lamin A have been shown to inhibit adipocyte 
and megakaryocyte differentiation, (Swift et al. 2013, Shin, Spinler, et al. 2013) while 
promoting erythrocyte differentiation. Unpublished data from Dr Schirmer showed that 
lamins also take part in chromatin organization and regulation. NETs have been shown 
to recruit chromosomes to the nuclear periphery for silencing, and loss of NETs resulted 
in abolishment of this recruitment and regulation (Robson et al. 2016, Zuleger et al. 2013). 
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5.2. Lamin A, diseases and tissue-specific interaction 
postulate 
Lamin A has the most number of distinct mutated genes linked to diseases in humans. 
As mentioned earlier in chapter 1, there are over 500 mutations currently reported in 
LMNA linked to multiple diseases. Some of these diseases have overlapping clinical 
phenotypes. However most preferentially affect distinct tissue types (table 15). The 
tissue-specific mechanism(s) of how mutations in lamin A cause disease still eludes us. 
Mutations in lamin A are spread out over the entire protein with at least 1 reported case 
for almost every amino acid (figure 22E).  
The current disease mechanisms proposed are gene regulation, stem cell maintenance 
and mechanical stress. Lamins and other NE proteins have been shown to interact with 
chromatin and chromatin associated factors (Burke and Stewart 2013). This interaction 
may have an important function in regulating gene expression by silencing specific genes 
at the nuclear periphery (Towbin, Meister, and Gasser 2009). Disruption in NE/lamina 
interaction with the silenced genes at the nuclear periphery may mediate pathologies and 
disruption in this interaction has been reported in several NE-linked diseases (Wilkie and 
Schirmer 2006). This suggests that gene regulation is an important mechanism in 
mediating pathologies. Mechanical instability is a good model to explain muscular 
dystrophies, as the nuclear lamina is responsible for maintaining nuclear stability, so 
mutation in lamins can increase fragility of the NE. Indeed, it has been reported that loss 
of NE structural integrity could lead to muscular dystrophies (Sullivan et al. 1999). Studies 
simulating the forces exerted on cells in contracting organs on lamin-deficient models 
have shown that lamin-deficient cells are more susceptible to mechanical forces 
(Lammerding et al. 2005, Lammerding et al. 2004, Broers et al. 2005). In addition, 
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different lamin subtypes have different mechanical strengths and tissues differ in lamin 
composition, which may provide a means to mediate tissue-specificity of diseases 
(Schirmer and Gerace 2004, Guilly et al. 1987, Broers et al. 1997).  
The dilemma of these pathologies is not only, how do mutations in the same gene cause 
such a wide range of diseases that can affect vastly different tissue types such as muscle 
and fat to nerve tissues (Table 12), but also how do these supposedly widely expressed 
proteins cause such specific tissue restricted pathologies? This dilemma has confounded 
understanding of these diseases and is yet to be clarified. This led to the hypothesis that 
other factors must play important roles in mediating disease pathology, more importantly, 
these other factors must be tissue-specific. Further support for this hypothesis comes 
from the fact that multiple genetic variants of cardiomyopathy with conduction defects are 
also caused by mutations in LAP2- (Taylor et al. 2005) a known interacting partner of 
lamin A/C (Dechat et al. 2000). Also genetic variants of EDMD caused by proteins such 
as emerin, lamins and LINC complex members have been identified (Mejat and Misteli 
2010, Meinke, Nguyen, and Wehnert 2011). This suggests that disease pathologies are 
mediated by disruption of interactions in protein complexes and not the individual proteins 
themselves. Since these complexes consist of widely expressed proteins, other yet 







Table 15. Mutations in lamin A causes a wide range of disorders  
Laminopathies 
Autosomal Emery–Dreifuss muscular dystrophy 
Cardiomyopathy dilated 1A 
Limb girdle muscular dystrophy type 1B 
Congenital muscular dystrophy 
‘Heart–hand’ syndrome 
Dunnigan-type familial partial lipodystrophy 
Lipoatrophy with diabetes and other features of insulin resistance 
Mandibuloacral dysplasia 
Charcot–Marie–Tooth disorder type 2B1 
Hutchinson–Gilford progeria syndrome 
Atypical Werner syndrome 
Restrictive dermopathy 







5.3. Known lamin A-associated proteins 
One of the groups of proteins that have been found to bind lamins is the LEM domain 
family. This evolutionarily conserved group of proteins is characterized by a bihelical LEM 
motif. This motif is responsible for mediating binding to the protein BAF. The LEM domain 
family has been shown numerous times to depend upon members of the lamin family for 
localization and their functions (reviewed in (Brachner and Foisner 2011, Wilson and 
Foisner 2010)). In mammals, 5 members have been identified, emerin, LAP2, LEMD1, 
MAN1 and LEM2 (Barton, Soshnev, and Geyer 2015). Some of these proteins have been 
shown to partly overlap in their functions (Lin et al. 2000, Mansharamani and Wilson 
2005). LEM domain residence of the INM works with lamins to recruit heterochromatin to 
the nuclear periphery. Interactions with chromatin have been shown to be via LEM-BAF 
interaction, however, direct interactions have also been reported for LAP2 (Cai et al. 
2001). One of the most studied LEM domain members is emerin, which has been shown 
to be the cause of X-linked Emery-Dreifuss muscular dystrophy. 
Another lamin partner is lamin associated polypeptide 1 (LAP1), the first protein identified 
to interact with lamins (Foisner and Gerace 1993, Martin, Crimaudo, and Gerace 1995). 
LAP1 interacts with torsin A, a mutant of which has been linked to DYT1 dystonia 
(Goodchild and Dauer 2005), a disease affecting the nervous system. LAP1 also forms 
a complex with emerin, this has been shown to be important in the maintenance of 
striated muscle and that in emerin-null mice, LAP1 knock out causes muscular dystrophy 
(Shin, Mendez-Lopez, et al. 2013). Recently the isoform LAP1B has been linked directly 
with muscular dystrophy in humans (Kayman-Kurekci et al. 2014). 
The LINC complex proteins are also important lamin interactors. They form the bridge 
between the ECM and the nucleoskeleton. Lamin interaction is achieved via the SUN 
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proteins with the KASH proteins connecting with the cytoskeletal components (Crisp et 
al. 2006, Tapley and Starr 2013). The SUN-KASH family of proteins have a wide range 
of functions, which include mechanotransuction, nuclear positioning (Brosig et al. 2010, 
Lombardi et al. 2011, Tapley and Starr 2013). Recently, the LINC complex proteins have 
been found to cause muscular dystrophy (Meinke et al. 2014, Puckelwartz et al. 2009, 
Zhang et al. 2007). What is more interesting is that many isoforms of the LINC complex 
members are preferentially expressed in different tissues (reviewed in(Mejat and Misteli 
2010, Rothballer, Schwartz, and Kutay 2013, Tapley and Starr 2013)) and this fits with 
the hypothesis that tissue-specific components must be required for disease pathology. 
Emerin, an INM protein, and BAF have also been found to bind lamin A (Clements et al. 
2000) (Simon and Wilson 2013). Emerin and LMNA null cultured cells showed increases 
in NE defects and mechanotransduction (Lammerding et al. 2005) (Lammerding et al. 
2004), suggesting important roles for both lamin A and emerin in NE structural integrity 
and also mechanotransduction. Mutations in the LMNA gene have been linked to many 
tissue-specific diseases including EDMD.  
One other partner is the protein Lamin B receptor (LBR). LBR has 8 transmembrane 
domains and mutations in the gene have been linked to diseases (Hoffmann et al. 2002, 
Waterham et al. 2003). Interaction studies have also identified hundreds of potential 
nuclear lamins interacting partners (reviewed in (Simon and Wilson 2013, Wilson and 
Foisner 2010)). Furthermore, Tmem120A an adipocyte-specific NET identified in the 
Schirmer proteomic studies has also come up as a hit in one of these studies (Dittmer et 
al. 2014). Tmem120A has been reported to be upregulated in adipogenesis and also has 
chromosomal repositioning effects. Knockdown of Tmem120A also inhibits adipogenesis 
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in mouse 3T3-L1 cell line (Batrakou et al. 2015). With many potential lamin binding 
partners, I wanted to tests the following hypotheses: 
1. Tissue-specific diseases arise through interactions between ubiquitously 
expressed proteins such as lamin A and tissue-specific NET components. 
2. The interactions between the NETs and lamin A will be disrupted in the 
presence of disease causing mutations. 
5.4. Designing a solid phase binding assay to measure 
interactions between lamins and nucleoplasmic 
regions of NETs 
There are many ways of measuring interactions between proteins currently available. The 
most straightforward being pulldowns, while other technologies include surface plasmon 
resonance (SPR) and isothermal titration calorimetry (ITC). I set out to design and test a 
solid phase style binding assay which would be able to be quantitative while, remaining 
affordable and quick. The assay was based on previous solid phase work carried out by 
Taniura et al 1995 (Taniura, Glass, and Gerace 1995) where a similar set up was used, 
however, in that set up, the detection was via radioactivity. With the advent of fluorescent 
probes, this solid phase technique was adapted for the purpose of measuring interactions 
between NETs and lamins. I wanted to design an assay which could produce results 
interpretable by Michaelis-Menten kinetics, which would allow for binding constants. If the 
results were corroborated using techniques such as SPR and are reproducible, testing 
would be expanded to include more NETs and chromatin. 
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The experimental design consists of binding full length lamin A to a nickel coated surface 
to form the solid phase (figure 21A). This set up is advantageous because full length 
lamin A is known to be insoluble, also mutations are present throughout the protein.  
A nucleoplasmic NET fragment with a 
tag was added on top of the solid phase 
(figure 21B). We chose largest 
nucleoplasmic fragment which was 
determined by prediction software 
TMHMM. Binding was then detected 
using antibody against the tag and a 
further antibody coupled to a 
fluorophore against the species to 
which the tag antibody was raised figure 
21C). Fluorescence signals from the 
fluorophore Alexa 488 was read using 
plate readers at 490 nm wavelength. 
Having tagged NET fragments not only 
allows for easy purification, but also for 
consistency of detection. Antibodies 
raised directly against a target can have 
huge variation between different 
Figure 21. Schematic of the binding assay used 
in this study. (A) Binding of lamin (black/blue) to 
the nickel coated surface. (B) NET fragments 
(orange/yellow) are added on top of the lamin 
solid phase. (C) Detection of binding using 
fluorescently tagged antibody (purple/green). 
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batches, as well as between antibodies. By using only one antibody against a tag, this 
variation is greatly reduced.  
 
For this study, a range of lamin A mutants were chosen (Table 16) that have been linked 
to very distinct diseases. The mutations were also chosen to test a wide range of position 
along the protein (figure 22D). It is postulated that NETs interact with WT lamins, 
however, tissue-specific NETs will lose or have greatly reduced binding to mutants 
affecting the tissue in which they are expressed.  
The mutants were generated using a site-directed mutagenesis kit (chapter 2) and 
expressed from pET28b vector in BL21 cells. Purification of the lamins was carried out 
from inclusion bodies and then solubilised in urea. The purity of the lamins were checked 












Table 16. List of disease mutations generated in this study 
Lamin mutation Disease linked 
E203K Dilated Cardio Myopathy 
R298C Charcot-Marie Tooth 2B1 
R377H Emery Dreifuss Muscular dystrophy 
R435C Restricted Dermopathy-like proregia 
R453W Emery Dreifuss Muscular dystrophy 
G465D Familial Partial lipodystrophy (FPLD) 
R482Q Familial Partial lypodystrophy 







Figure 22. Purification of lamins and GST-tagged Tmem120A. (A) Lamin A WT and disease 
mutant purification from inclusion bodies. (B) Purification of GST tagged Tmem120A on 
glutathione matrix. (C)Test binding of GST tag to lamin WT shows high background 
unspecific binding (top graph). Tmem120A-GST also showed high unspecific binding to 
the wells where no lamin was present (bottom graph) (D) Location of the lamin mutants 
chosen in this study. The majority of mutations are clustered around the C-terminal tail 
segment. (E) Distribution map of mutations with their associated number of reported cases. 
Mutations can be found throughout the protein. Distribution map was generated using 
tools from http://www.umd.be/LMNA/. 
5.5. GST tag shows high unspecific background 
binding to WT lamin A 
NETs have been notorious for being insoluble, with many previous studies into protein-
protein interactions requiring harsh refolding steps in order to produce usable proteins 
(Holaska et al. 2003). Additionally, proteins expressed in bacteria may not have post-
translational modifications, harsh treatment can potentially alter the protein chemistry and 
skew any interaction results. I decided to clone nucleoplasmic domains of NETs coupled 
to tags that have been cited to improve solubility (reviewed in (Costa et al. 2014)). As the 
assay is reliant on detecting a tag to produce the readout signal, the tag itself should not 
bind to the lamins.  
The NET fragments were first cloned into pGEX-4T1 vector expressing a C-terminal GST. 
This enabled the expression and purifications of the NET fragments (figure 22B) with high 
purity. However, when testing for background binding towards WT lamin A (figure 22 top 
graph), Tmem120a-GST also showed high background binding where no lamin was 
present (figure 22C, bottom graph), the tag alone gave very high background. This was 
not alleviated with more stringent buffer conditions (data not shown). Maltose binding 




5.6. Transfer of NET fragments into MBP tag vector 
and background testing. 
The MBP tag was tested for background binding to WT lamin A using several 
concentrations (0, 9, 45, 90, 180, 450, 900, 1800 pM). Using emerin as a positive control, 
a protein which has been extensively shown to interact with lamin A (Clements et al. 
2000, Holaska et al. 2003), the response of emerin tagged with MBP when exposed to 
lamin A in the solid phase binding assay was significantly different to the response given 
by the MBP tag alone (figure 23C). The MBP tag alone showed increases in unspecific 
lamin A binding at the higher concentration (>500 pM), however, this interaction appears 
to be greatly reduced in the presence of a NET fragment such as emerin. Testing showed 
that emerin gave a much higher response than the tag alone, more significantly and much 
earlier, at low concentrations. At higher concentrations, there will inevitably be unspecific 
binding, however this interaction between the tag and the solid phase will be insignificant 
and most of the signal will be of the NET binding. After discussion, this background 
binding of the MBP tag was deemed to be acceptable, testing was expanded to other 
NETs. MBP-tag binding to wells in the absence of lamin A was not significantly different 
than a blank well with only TBS (figure 23D) 
The nucleoplasmic NET fragments were subsequently cloned into pMAL-CRI vector 
expressing an MBP tag. It was possible to express and purify the fragments with high 
purity (figure 23A). One of the NET fragments, Tmem38A is very small and highly 
charged, and when run on SDS-PAGE gel is indistinguishable from the MBP tag alone, 
but its expression was confirmed by western blotting using affinity-purified antibodies 
produced in chapter 3 that specifically recognize this region of the protein. Although 
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indistinguishable via laemmli gel, Tmem38A was indeed expressed and purified (figure 
23B).  
Table 17. Protein used and their expected molecular weight 
Protein Expected molecular weight (kDa) 
His-Tagged Lamin A inc mutants (aa1-646) ~72 kDa 
MBP-Tagged Tmem38A (aa233-299) ~49.2 kDa 
MBP-Tagged Tmem120A (aa1-137) ~58.3 kDa 
MBP-Tagged Emerin (aa1-224) ~67.7 kDa 
MBP-Tagged Lap2(aa1-398) ~86.5 kDa 
MBP-Tagged LBR (aa1-211) ~65 kDa 






Figure 23. (A) Purification of MBP tagged NET fragments and testing of background binding 
to WT lamin. Laemmli gel of the purified NET fragments showing a main band of expressed 
protein and the background impurities present in each preparation. (B) Western blot using 
both anti-Tmem38A (GREEN) and anti-MBP (RED) antibodies. Although they run at the 
same apparent molecular weight Tmem38A is not detected in the purification of the tag 
alone. (C) Response curves of emerin-MBP (black) and MBP tag (red) binding to WT lamin 
A. (D) MBP binding to wells without lamin A present was not significantly different than 
wells with nothing in them. 
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5.7. Tmem120A has reduced binding to lipodystrophic 
mutants 
While testing the NETs, it was found that from experiment to experiment the baseline 
readout can be highly variable (fluorescence intensity could be +/- 50% between 
experiments). This made it impossible to calculate an accurate absolute Kd. Additionally, 
some of the binding curves obtained do not fit a classic Michaelis-Menton curve (data not 
shown). However, a trend in Tmem120A was found. Although the numbers obtained from 
each experiment were different, in all experiments the Bmax of Tmem120A was always 
lower than WT lamin when tested against G465D and R483Q, two lipodystrophic mutants 
(figure 24 and 34). In contrast, the Bmax of Tmem120A binding to the myopathy, 
neuropathy and progeria lamin A mutants did not differ when compared to WT (figure 35).  
The bulky nature of this sandwich assay system may hide any differences at low 
concentrations. The differences in Bmax persisted with repeats, however, the differences 





Figure 24. Tmem120A has a lower Bmax against lipodystrohic mutants of lamin A. 
Tmem120A showed a higher binding saturation plateau to WT lamin A than the 
lipodystrophic mutants G465D and R482Q. Graph shows representative experiment with 





5.8. Surface Plasmon Resonance revealed two step 
binding of NETs to lamin A 
To try and get a clearer picture of the results obtained in the solid phase binding assay, 
SPR experiments were carried out to try and replicate the results using a different 
approach. SPR is a sensitive assay which measures the differences in refractive changes 
when analytes bind to a predetermined surface in real time. Much in the same way as 
the solid phase assay, His-tagged lamin A was bound to a NTA-chip (70 Response unit 
(RU)) in urea as a solid phase. After binding, buffer tests (running buffer, Section 2.6.2) 
were ran and found no significant detachment of lamin A from the basal matrix.  
Attempts to validate the interactions found with the solid phase assay were carried out, 
beginning with emerin (figure 25) as it was previously tested using SPR (Clements et al. 
2000). The experiment was composed of 90 s injections followed by 90 s washing step. 
After 5 sequential injections (2-fold concentration series of NETs fragments ranging from 
0.3125 µM – 5 µM), a plateau was not found. Tmem120A (adipocyte specific) and 
Tmem38A (muscle specific) were also tested, both against WT lamin A, lipodystrophic 
mutants and muscular dystrophic mutants respectively (figure 27 and 28). No differences 
were found using SPR in the interactions between WT lamin A and these NETs when 
compared with the disease mutants. The response curves showed a two-step reaction 
with a quick initial binding followed by a slower interaction.  
I hypothesized that this could be due to either 1) the unstructured coiled-coil domain of 
lamin A may be promiscuous in tested conditions and/or 2) the protein sample is not 
homogenous and the steps are due to different species having different interactions. To 
try and eliminate this unspecific binding, emerin’s binding to lamin A without its 
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unstructured coil domain (figure 26) was first tested. Removing the coiled-coil domain did 






Figure 25. Response curve of emerin-MBP binding to immobilised WT HIS-lamin A. 5 
sequential injection of emerin tagged with MBP in a two-fold dilution series from 5µM-
0.365µM (lowest concentration injected first). No binding saturation was seen. All steps 





Figure 26. Response curve of emerin-MBP binding to immobilised HIS-lamin A delta coil. 5 
sequential injections of emerin tagged with MBP in a two-fold dilution series from 5µm-
0.365µm (lowest concentration injected first). No binding saturation was seen. All steps 




Figure 27. Response curve produced by Tmem120A-MBP binding to immobilised WT HIS-
lamin A and lipodystrophic mutants (HIS-G465D and HIS-R482Q). 5 sequential injections of 
Tmem120A tagged with MBP in a two-fold dilution series from 5µm-0.365µm (lowest 






Figure 28. Response curve produced by Tmem38A-MBP binding to immobilised WT HIS-
lamin A and muscular dystrophic mutants (HIS-R377H and HIS-R527H). 5 sequential 
injections of Tmem38A tagged with MBP in a two-fold dilution series from 5 µM-0.365 µM 




5.9. Size exclusion chromatography revealed large 
protein complexes. 
As the SPR experiments yielded ambiguous results, size exclusion chromatography to 
find out the oligomerization state of the protein samples was carried out. Samples of MBP 
tagged emerin and Tmem120A were run through superdex 200 (10 kDa- 600 kDa) 
column in the same buffer used for the SPR experiments. The elutions were then 
analysed by protein electrophoresis. 
For both emerin-MBP and Tmem120A-MBP (predicted monomeric mass can be found in 
table 17), it was found that all the full-length NET fragments were found in the void volume 
(7.8 ml for the superdex 200 column) (Figure 29 and 30). This meant that the protein 
complexes ran at an apparent Mw of over 600 kDa. The majority of proteins that made 
up the elution peaks were comprised of lower Mw species. The results raised questions 
on the oligomeric status of the protein fragments.  
Previous attempts at purifying emerin-MBP which reported monomeric forms utilized 
either low pH or low salt buffer (Holaska et al. 2003, Berk et al. 2014). I also postulate 
that as the plate based binding assay used has a higher tolerance for detergent compared 
with SPR, the presence of detergent could help maintain monomeric protein fragments 
and so could explain why differences in the assay that were not recapitulated in the SPR. 
Attempts to purify emerin-MBP into different buffers was carried out. The buffers tested 
include; low salt (20mM Tris, 30mM NaCl), detergent containing buffer (20mM Tris, 
200mM NaCl, 0.02% TX-100) and low pH phosphate buffer (pH 6.3). Purification of 
emerin into these buffers yielded lower amounts of full length fragments (data not shown). 
Assuming solubility, attempts to separate the full-length fragments from the rest of the 
material present in the samples were carried out. A superose6 column was utilized to 
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give higher resolution in case of large soluble complexes. It was observed from the elution 
profile of the low salt buffer (figure 31), detergent containing buffer (figure 32) and low pH 
phosphate buffer (figure 33) that more proteins were running at the expected MW for 
monomers. No void peak (~6.7 ml for the superpose 6 column) was present in the 
detergent buffer and the low pH buffer. The low salt buffer showed a much-reduced void 
peak. Analysis of the elution peaks by protein gel electrophoresis however revealed that 




Figure 29. Size exclusion chromatography of emerin-MBP over a superdex 200 column in 
TBS. (A)The elution profile showed two main peaks, 1B2-1B7 being the void volume and 
1C1-1C8 being the elution peak. The elution peak showed a slight shoulder where some of 
the full-length protein remained (1C1-1C3). (B) Protein electrophoresis analysis of the 




Figure 30. Size exclusion chromatography of Tmem120A-MBP over a superdex 200 column 
in TBS. (A) The elution profile of Tmem120A showed the majority of the protein was present 
in the void volume with a small elution peak 1C1-1C7. (B) Protein electrophoresis analysis 






Figure 31. Size exclusion chromatography of emerin-MBP (*) over a superpose6 column in 
low salt buffer (20mM Tris, 30mM NaCl). (A) Chromatography profile of emerin showed an 
improved profile with a smaller void volume B9-B1 with the majority of the protein in the 
elution peak C1-C12, D12-11. Analysis of the void volume (B) and the elution peak (C) 






Figure 32. Size exclusion chromatography of emerin-MBP (*) over a superpose6 column in 
detergent containing buffer (20mM Tris, 200mM NaCl, 0.03% TX-100). (A)The elution profile 
showed 1 main elution peak with a shoulder. Protein analysis of the elution peaks showed 
the cleanest full length fractions was present in the shoulder C6-C9. (B) Protein 




Figure 33. Size exclusion chromatography of emerin-MBP (*) over a superpose6 column in 
low pH buffer (10mM NaHPO4, pH6.3). (A) Elution profile of emerin in low pH buffer showed 




5.10. Qualitative analysis of the solid phase binding 
assay results. 
With the limitations of the protein fragments, it was not possible to get a clear interaction 
picture from the SPR, or perform quantitative analysis with the solid phase binding data. 
It was hypothesized that the differences in results from the assay compared with the SPR, 
could be due to detergent tolerance. The solid phase assay contained extensive washing 
steps which used above CMC level of detergent, as it does not interfere with the read 
out. This is not possible with the SPR method. I postulate that the washing step may allow 
time for the non-specific binding to be removed and/or maintain monomeric form of the 
full-length protein fragments. Another barrier against quantitative analysis was the 
differences in read out between experiments.  
Using the solid phase approach, I believe patterns in binding between NETs and lamin A 
can still be analysed qualitatively. By normalizing binding of NETs to WT lamin A at Bmax 
to 100% for each experiment and comparing the binding to that of lamin A mutants, I 
wanted to see if the differences observed with Tmem120A binding to lipodystrophic 
mutants was significant. ANOVA analysis of the Bmax obtained using the plate based 
assay revealed significant differences between the binding of Tmem120A-MBP to WT 
HIS-lamin A and that to the G465D (***) and R482Q (**) mutants (figure 34). No significant 
differences were seen when comparing between the binding of the mutants. The binding 
of Tmem120A to other non-lipodystrophic mutants was also analysed. It was found that 
there were no significant differences when comparing against WT binding (Figure 35). 
The muscle specific NET Tmem38A did not reveal any differences in binding to disease 





Figure 34. Qualitative analysis of multiple experiments of Tmem120A-MBP binding to 
immobilised HIS-lamin A WT and lipodystrophic mutants (G465D and R482Q). One-way 
ANOVA analysis revealed significant differences between binding of Tmem120A to WT 
lamin A when compared to that of its binding to lipodystrophic mutants. No significant 
differences were found between the binding of the mutants. Saturation concentration was 





Figure 35. Qualitative analysis of multiple experiments of Tmem120A-MBP binding to 
immobilised HIS-lamin A WT and other non-lipodystrophic mutants revealed no significant 
differences. One-way ANOVA analysis revealed significant differences between binding of 
Tmem120A to WT lamin A when compared to that of its binding to non-lipodystrophic 







Figure 36. One-way ANOVA analysis of Tmem38A-MBP binding to HIS-lamin A WT and 




5.11. Results summary 
In this chapter, I showed the viability of the solid phase binding assay as a method of 
measuring interactions between NETs and lamin A. Using emerin as a positive control, I 
was able to show that the MBP tag used had minimal background binding compared to 
emerin/WT lamin A interaction. However, the measurements obtained from the binding 
assay were found to be very variable making a quantitative analysis difficult.  
I postulated that the variability in the binding assay measurements could be due to 
differential washing steps between experiments. To test this, I carried out SPR 
experiments which measures interactions in real-time, eliminating washing steps. The 
SPR results showed a concentration dependant two stage binding for all 3 tested proteins 
(emerin, Tmem120A and Tmem38A).  
Suspecting heterogeneity, size exclusion analyses were carried out. The data showed 
the fragments of emerin and Tmem120A used were forming large, soluble complexes. 
This improved when using detergent or low pH buffers to purify the protein fragments, but 
not in low salt buffers. These buffers, however, lowered the yield of the protein 
purification.  
Qualitative analysis of the binding data revealed a reproducible pattern of reduction in 
Tmem120A binding to the lipodystrophic mutants G465D and R482Q, but not to lamin A 
WT and other non lypodystrophic mutants. The reduction in binding of Tmem120A to 
G465D and R482Q could be important, as it has been previously shown that knockdown 
of Tmem120A inhibits adipogenesis. Tmem38A testing did not reveal significant 
differences in binding between WT lamin A and mutants. 
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Time constraints resulted in several flaws in the experimental set up of both the solid 
phase binding assay and the SPR experiments. The lack of a comprehensive set of 
controls for both set up mean that interpretations of any differences observed may not be 
as large or significant as initially seem. Testing for background binding of Tmem120A-
GST did not include a GST tag only control binding to a blank well and as such, some 
background binding to an empty well could be due to the Tmem120A NET fragment as 
well as the tag. However, later experiment with Tmem120A-MBP, with MBP tag only 
control versus empty well showed minimal binding of both to a blank well without lamin 
present. This points to the GST tag being the main source of the background binding. 
With the time constraint, arguments can be said about running the SPR experiment first 
to see if it is worth it to carry on with the project. In this case, we did not find any significant 
differences in binding of NETs to lamin A. However, in the presence of observable 
changes, this approach would take more time as proper controls would be required to 








6.1. Tissue-specificity of NETs 
Extensive research carried out by the Schirmer lab has previously revealed that only 
about a third of NE proteins are shared among the liver, muscles and blood leukocytes. 
Further studies have shed insights into the roles and functions of a minor portion of these 
proteins. NET5/SAMP1 is important in centrosome anchoring and associated with TAN 
lines, with implications in nuclear migration (Borrego-Pinto et al. 2012). Others, such as 
Tmem120A, have effects on transcription and cell fate (Batrakou et al. 2015). Though the 
functions of tissue-specific NETs are becoming an increasingly important field, as of yet 
many have not been directly tested and NE residence has only been determined by 
proteomic approaches. 
I set out to test the hypothesis that tissue-specific disease pathology could arise from 
properties of tissue-specific NETs, which differ between tissue sub-types. I confirmed 
through immunofluorescent staining using specific antibodies on muscle tissue sections 
and myoblasts/myotube cell cultures, the NE localisation of Tmem38A, NET5, WFS1 and 
Tmem214. Although expressed at the NE in muscles nuclei for NET5, Tmem214 and 
WF1, they were also found at the NE of nuclei in the surrounding connective tissues and 
in undifferentiated myoblasts.  
Tmem38A was found to be exclusively expressed in differentiated muscle nuclei with 
other work done in the lab showing Tmem38A upregulation during myogenesis (Robson 
et al. 2016), suggesting that it plays an important role in muscle function and regulation. 
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Although found at the NE of nuclei in the surrounding connective tissues, knockdown of 
WFS1 in combination with Tmem38A was shown to almost completely block myogenesis 
(Robson et al. 2016). Potentially, it may require subtle changes in a combination of 
several tissue-specific NETs to cause a disease. Unpublished data from the Schirmer lab 
has also identified several mutations in Tmem38A, WFS1 and NET5 through genome 
analysis of families with unlinked causes, suggesting these NETs may still be involved. 
It is yet to be seen if there is another layer to the complexity of the NE proteome. Previous 
proteomic research and this study could not answer whether there might be differences 
in the levels of the more widely expressed NETs in different tissues and cell types. 
Potentially, a NET may be expressed in more than one type of tissue, but its expression 
levels regulate its roles and functions. Indeed, a prime example is lamins. As mention in 
chapter 5, different expression levels of lamins can have differing effects on cell fate and 
function (Swift et al. 2013, Shin, Spinler, et al. 2013). The lack of differences seen in the 
samples tested may be an indicator of small sample size. This study may be more suited 
for long term time scale to allow for a large sample library to be collected and more 
extensive testing. 
6.2. Relevancy of biopsy in modern diagnostic 
medicine 
Diagnosis of disease has been increasingly reliant on sequencing. New technology has 
made it possible to sequence faster and more cheaply than ever before. It could be 
argued that invasive techniques such as biopsy are no longer required. This is definitely 
the case for diseases with a clear and documented single source such as 
Duchenne/Becker’s muscular dystrophy, where there is only one known linked gene 
(Dystrophin). Other diseases however, are not so clear cut. A heterogeneous disease 
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such as EDMD for example currently has eight linked genes responsible for 
approximately 50% of all cases, with half of EDMD cases still unlinked. With many 
potential pathways which could lead to variable manifestation of phenotypes, the 
relevancy of what a simple biopsy staining can tell us is questionable.  
While genetic approaches have been taken to identify causal genes in many cases, 
biopsies are still required to confirm localisation and expression of proteins in research. 
It is still important to study proteins in their native, mature environments. While tissue 
culture techniques have improved, they still cannot replicate the conditions that are 
happening in mature tissues. Comparisons of affected muscle groups of EDMD and 
LGMD revealed no clear distinguishing features. This suggests that no overt mechanical 
mechanism is involved in these diseases and maybe there is a genome organization 
aspect to them. 
Another problem with biopsies is that, for many muscular disease studies, the accepted 
normal control samples consist mostly of muscle excluded sections. This makes it 
questionable whether they are truly normal and have no effects on any observations 
made.  
In conclusion, biopsies should be used, albeit sparingly, in conjunction with less invasive 
techniques to fully understand the pathology of diseases. To overcome the sample size 
dilemma for non-clinician researchers, all biopsies should be made available through 
biobank and this should be made clear to the patient when obtaining permission.  
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6.3. Problems of working with NETs fragments 
During the course of this study, attempts at purifying NETs has brought up many 
obstacles and questions; the first being the solubility of NETs. Purification techniques 
used in this study failed to conclusively purify mono-disperse NET samples. Although 
NETs tagged with MBP appear to be soluble, further analysis by size exclusion 
chromatography showed the protein fragments forming large soluble complexes which 
prevented quantitative analysis.  
Previous research using NET fragments generated data which on inspection, showed 
similar results to those obtained using SPR in this study (Clements et al. 2000). The 
response profile of their data also showed a two-stage response, suggesting the protein 
samples used were not mono-disperse. Other studies into binding of emerin to lamins 
which reported soluble emerin used various lengths of the nucleoplasmic region, all of 
which are shorter than the fragment used in this study (Holaska et al. 2003, Wilkinson et 
al. 2003, Haraguchi et al. 2004, Demmerle, Koch, and Holaska 2012, Berk et al. 2014). 
Apart from being bacterially expressed, which means proteins could lack post-
translational modifications, these previous studies into emerin interactions utilized shorter 
fragments of the protein, often just the LEM domain. While molecularly dissecting protein 
down to monodispersic fragments may be able to shed light on small areas of 
interactions, it is questionable whether these interactions are the native state of the 
proteins within the cell. Lamin A and NETs are by nature insoluble proteins, unpublished 
data from the lab shows that lamin A unstructured regions have a tendency to fold over 
and interact with other regions and so binding data may not represent normal interactions.  
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6.4. Interactions between NETs and lamins 
I demonstrated in this study the interaction between NETs and lamin A using two 
methods, SPR and a solid phase binding assay. Attempts at obtaining quantitative 
binding affinity using both methods were made more complicated with the discovery that 
MBP tagged NETs samples have a tendency to form large, soluble aggregates. 
Experiments are in motion to further dissect the binding sites of NETs and lamin A. 
Preliminary data (not shown) from the Schirmer lab appears to indicate that for some 
NETs, the C-terminal domain of lamin A is sufficient for interaction. Other studies have 
also shown that not all of the nucleoplasmic domains of NETs are required for binding to 
lamin, such as emerin which only requires amino acid 1-188 (Clements et al. 2000).  
Using a qualitative approach to analyse the binding data, it was found that Tmem120A 
had reduced binding to lipodystrophic mutants of lamin A. This supports the hypothesis 
that disruption of interactions between widely expressed, disease linked proteins, with 
more tissue-specific NETs, may be a factor in manifestation of tissue-specific pathology.  
It would be interesting to narrow down the binding sites of NETs on lamin A and compare 
them to the mutations present. Whether disease causing mutations disrupts specific 
binding sites or the overall structure of lamin A, which in turn could disrupt NET binding, 
is still to be seen. The solid phase binding assay did not find reduced binding of 
Tmem120A and Tmem38A to WT and other non-lipodystrophic mutants, suggesting that 
these interactions require other specific binding sites and which are not disrupted by the 
mutations G465D and R482Q. The lipodystrophic lamin A mutant R482Q has also been 
shown to disrupt interaction with an adipocyte differentiation factor sterol response 
element binding protein 1 (SREBP1) (Lloyd, Trembath, and Shackleton 2002, Vadrot et 
al. 2015), as well as deregulating Fragile X-related protein 1 (FXR1P), resulting in a 
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myogenenic gene expression response in preadipocytes (Oldenburg et al. 2014). When 
combined with published data showing Tmem120A is important in adipocyte 
differentiation (Batrakou et al. 2015), it suggests that Tmem120A may be part of the 
regulatory complex which, when disrupted, results in lipodystrophy. 
Mutational analysis of unlinked families carried out by the Schirmer lab revealed potential 
causal mutations in several NETs (WFS1, Tmem38A and NET5). It would be interesting 
in the future to carry out studies to see whether mutations in the NETs alter binding to 
WT lamin A. Altered binding in the presence of NET mutations in unlinked patients could 
indicate causality. Further experimentation is required to see if the reduced binding has 
any contribution to disease pathology. However, this data represents a potentially exciting 
step forward in the understanding of tissue-specific pathology. 
6.5. Future directions 
The question of establishing normal expression and distributions of NETs in tissue, and 
whether changes in patient samples can be used reliably to indicate specific disease, still 
require further study. In hindsight, even though the sample size used in this study is 
greater than many previous reports, it is still not enough to establish a baseline pattern 
for the tested NETs. Further expansion to this study should take steps to increase the 
number of collaborations with clinicians to build up a bigger sample size. Establishing 
ethical approval with muscle banks such as the one in London and Munich would 
significantly help in this matter. As these orphan diseases are often rare and patients may 
not be readily available, it could also be argued that without a significant quantifiable 
difference, it may not be worth carrying out invasive procedures such as biopsies. 
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A study of this scope would also be best carried out long term; the requirements of 
generating specific antibodies against NETs are often complicated and time consuming, 
building up a portfolio of antibodies may take much longer than that allowed in a PhD 
program in the UK. Epitope masking has also been reported in certain cases and so great 
care needs to be taken when reporting negative signals (Tunnah et al. 2005). It is possible 
that certain NET distribution would only be seen with particular antibodies due to epitope 
masking. Generating such a panel of monoclonal antibodies would certainly take time. 
Identification and purification of NET fragments can be very problematic, as shown by 
this study. Nucleoplasmic fragments of NETs have shown tendency to be insoluble and 
my attempts have found that they form soluble aggregates. Generating antibodies against 
soluble aggregate could generate unspecific antibodies. On the other hand, the 
unstructured nature of NETs could mean that they may form large complexes natively 
and present native epitopes. For a study which hopes to decipher differences between 
samples, clean antibodies to native epitopes are required to make sure no false signals 
are detected, which is why large nucleoplasmic fragments were used in this study.  
The tendency of NETs to be insoluble or form large aggregates means that careful 
planning is required when purifying them. Although this study set out to design and build 
a system which would allow faster analysis of interactions, perhaps a more prudent 
approach would be to take time to molecularly dissect each individual protein separately 
to achieve monodisperse, soluble samples. However, the usefulness of this approach 
could also be called into question. In this study, I cloned and expressed the entire 
nucleoplasmic domain of NETs i.e. emerin aa1-224, which was shown to form soluble 
aggregates, despite the fact that it has been reported that emerin aa1-222 (almost all of 
the nucleoplasmic domain) could be purified as soluble monomers (Holaska et al. 2003). 
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The absence of 2 amino acids before the transmembrane domain may help with solubility 
and aggregation. Whether this is a universal rule which applies to all NETs needs further 
investigation.  
Future investigation into interactions of NETs and lamin A could also molecularly dissect 
the protein, to narrow down the binding site. However, the relevancy of interactions 
between much reduced protein, as mentioned previously, could be questionable. No 
conclusive structure of lamin A has been found so far, and as mentioned earlier in the 
chapter, it is not yet known whether mutations disrupt the whole protein structure or 
specific binding sites, with my results suggesting the latter. It would also be interesting to 
find out the effects of stacking multiple mutations. Tissue-specific diseases can have a 
wide range of clinical variations and multiple mutations present may cause more severe 
phenotypes, potentially in more than one protein. A genetic study had been carried out 
by the Schirmer lab which identified several mutations in NETs from unlinked EDMD 
patients.  
Future studies should also attempt to establish in vivo experiments to confirm the effects 
of loss/reduced NET/lamin interactions. Rescue experiments such as overexpressing WT 
NETs in a lamin mutant cell line, in the absence of WT, could give further indication of 






6.6. Final remarks 
While further studies are needed to understand the mechanisms behind tissue-specific 
diseases, the work presented in this thesis suggests changes to protein expression or 
distributions resulting in disease may be very subtle. No differences were found in the 
muscle sub-types which could explain why EDMD affects the gastrocnemius, while 
LGMD affects the upper leg muscles. This study also showed that care is needed when 
observing changes in the distribution of NETs, as they may not be indicative markers of 
disease. Finally, I showed that Tmem120A has a reduced binding to lipodystrophic 
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